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ABSTRACT 
Human papillomaviruses (HPVs) are genetically diverse, belonging to five distinct genera: 
Alpha, Beta, Gamma, Mu and Nu. We discovered ten novel Gammapapillomaviruses 
(Gamma-HPVs). Genomic characterisation and phylogenetic evaluation of the ten novel 
Gamma-HPV types were done: HPV211, HPV212, HPV213, HPV214, HPV215, HPV216, 
HPV219, HPV220, HPV221 and HPV222. These HPVs were previously identified in a study 
that was done on 218 penile samples (104 HIV negative and 114 HIV positive) using high 
throughput sequencing (Roche 454) of amplimers obtained using FAP59/64 primers which 
were designed to detect “cutaneous” or Beta- and Gamma-HPVs. Fifteen putative novel HPV 
types were identified from the short HPV L1 FAP fragments HPV211 (CT02, KY063000), 
HPV212 (CT03, KY063001), HPV213 (CT04, KY063002), HPV214 (CT06, KY063004), HPV215 
(CT07, KY063005), HPV216 (CT12, KY063010), HPV219 (CT01, KY062999), HPV220 (CT08, 
KY063006), HPV221 (CT09, KY063007) and HPV222 (CT155, AY009886) with prevalences 
varying from 0.5% to 4.1% of men sampled.  
Multiple full genome clones for each novel type were generated through whole genome 
amplification, cloning and next generation sequencing. Complete genome sizes were: 
HPV211 (7253 bp), HPV212 (7208 bp), HPV213 (7096 bp), HPV214 (7357 bp), HPV215 (7186 
bp), HPV216 (7233 bp), HPV219 (7108 bp), HPV220 (7381 bp), HPV221 (7326 bp) and 
HPV222 (7275 bp). Phylogenetically the novel Papillomaviruses (PVs) all clustered with 
Gamma-HPVs: HPV211 is most closely related to HPV168 (72% identity in the L1 nucleotide 
sequence) of the Gamma-8 species, HPV212 is most closely related to HPV144 (82.9%) of 
the Gamma-17 species, HPV213 is most closely related to HPV153 (71.8%) of the Gamma-13 
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species, HPV214 is most closely related to HPV103 (75.3%) of the Gamma-6 species, HPV215 
and HPV216 are most closely related to HPV129 (76.8% and 79.2% respectively) of the 
Gamma-9 species. HPV219 is phylogenetically most closely related to HPV213 (87% identity 
in L1 gene) of the Gamma-13 species, HPV220 to HPV212 (72%) of Gamma-17, HPV221 to 
HPV142 (80%) of Gamma-10, HPV222 to HPV162 (73%) of Gamma-19.  
The novel HPV types demonstrated the classical genomic organisation of Gamma-HPVs, with 
seven open reading frames (ORFs) encoding five early (E1, E2, E4, E6 and E7) and two late 
(L1 and L2) proteins. Typical of Gamma-HPVs, the novel types all lacked the E5 ORF and 
HPV214 also lacked the E6 ORF. We further examined variation of the novel types in clinical 
specimens from which they were identified. All the clones of HPV211, HPV214, HPV216, 
HPV219 and HPV221 were identical and showed 100% pairwise identity. The clones of 
HPV213, HPV215, HPV212, HPV220 and HPV222 had several differences. Analysis of 
mismatches between the nine genomic clones of HPV212 showed a total of 67 mismatch 
positions that varied along the 7208 bp genome and all the clones were unique. Analysis of 
mismatches between the 10 genomic clones of HPV213 showed a total of 51 mismatch 
positions that varied along the 7096 bp genome and it had 5 unique clones. The 6 genomic 
clones of HPV215 showed a total of 50 mismatch positions along a 7186 bp genome and it 
had 3 identical and 3 different clones. HPV220 had 4 different genomic clones that showed 
17 mismatch positions along a 7381 bp genome. The 5 different clones of HPV222 showed a 
total of 24 mismatch positions along the 7275 bp genome. Conserved domains observed 
among the novel types were the Zinc finger binding Domain and PDZ domains. A 
retinoblastoma binding protein (pRB) binding domain in the E7 protein was additionally 
identified in HPV214 and HPV222. PVs are thought to evolve slowly because they co-opt 
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high-fidelity host cellular DNA polymerases for their replication. Despite extensive efforts to 
catalogue all the HPV species that infect humans, it is likely that many still remain 
undiscovered.  We used the genome sequences of the ten novel viruses and related HPVs to 
analyse the evolutionary dynamics of these viruses at the whole genome and individual 
gene scales. We found statistically significant incongruences between the phylogenetic trees 
of different genes which imply gene-to-gene variation in the evolutionary processes 
underlying the diversification of Gamma-PVs. We were, however, only able to detect 
convincing evidence of a single recombination event which, on its own, cannot explain the 
observed incongruences between gene phylogenies. The divergence times of the last 
common ancestor (LCA) of the Alpha, Beta, Mu, Nu and Gamma genera was predicted to 
have existed between 49.7-58.5 million years ago before splitting into the five main 
lineages. The LCA of the presently sampled Gamma-PVs was predicted to have existed 
between 45.3 and 67.5 million years ago: approximately at the time when the simian and 
tarsier lineages of the primates diverged. The discovery, characterisation and classification 
of HPV211, HPV212, HPV213, HPV214, HPV215 HPV216, HPV219, HPV220, HPV221 and 
HPV222 add these novel types to the repertoire of the ever expanding Gamma-HPVs genus 
hence expanding our knowledge of these viruses. 
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Chapter 1: Introduction and Literature Review 
1.0 THE PAPILLOMAVIRIDAE  FAMILY 
Human papillomavirus (HPV) is a member of the Papillomaviridae family (Bernard et al., 
2010, de Villiers et al., 2004) which was once part of the larger family of Papovaviridae 
which was split into Polyomaviridae and Papillomaviridae by the International 
Committee on Taxonomy of Viruses (vanRegenmortel, 2002). ” According to the most 
recent ICTV classification, the Papillomaviridae family includes two subfamilies 
Firstpapilomavirinae with more than 50 genera and Secondpapillomavirinae with one 
genus and one species”(Van Doorslaer et al., 2018).  Genera are named according to the 
Greek alphabet from alpha to omega and following exhaustion of the alphabet the term 
dyo- and treis- (Greek for second time and third respectively) coined to accommodate 
the extra genera e.g. dyo-deltapapillomaviruses (Bernard et al., 2010). HPVs are 
distributed over 5 genera (Alpha, Beta, Gamma, Mu and Nu).  The other papillomavirus 
(PV) genera are from other mammals (2007.), birds (3) and reptiles (1) (Bernard et al., 
2010). Below the genus level are species and below the species level are types (de 
Villiers et al., 2004). Different genera have less than 60% similarity within the L1 gene, 
while species share between 60 and 70% similarity and types share types share between 
71% and 89% similarity. The ICTV is responsible for nomenclature of viruses down to 
species level, and below species level, the International HPV Reference Centre assigns 
unique HPV type numbers after the complete genome has been sequenced, cloned and 
confirmed by the Centre (Mühr et al., 2018).  
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1.1 NOMENCLATURE AND CLASSIFICATION OF NOVEL HPVS 
The recognition of a novel HPV type by the International HPV Reference Centre and the 
scientific community is based on availability of the full cloned genome, with the L1 gene 
sequence greater than 10% different or <90% similar from any previously described type 
(Bernard et al., 2010) (Figure 1.1).  
 
Figure 1.1  HPV L1 nucleotide sequence-based taxonomy. 
https://pave.niaid.nih.gov/#explore/taxonomy/submission_process 
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On observation of a potential novel HPV type, the DNA has to be amplified to obtain the 
complete genome; cloned into a plasmid; sequenced, submitted for official naming; 
classified into the correct phylogenetic position and have its genes annotated (Chen et al., 
2015). Determination of sequence similarity and differences requires a rigorous 
interrogation of the potential HPV type with sequences of all other HPV types in various 
databases (Harari et al., 2014). 
In 1985, an International HPV Reference Centre was established at German Cancer Research 
Centre (DFKZ) in Heidelberg and transferred to the Karolinska Institute (Stockholm) in 2012.  
The International HPV Reference Centre has to date discovered about 360 new previously 
unknown HPV types (Arroyo Muhr et al., 2014, Ekstrom et al., 2013b) and postulates the total 
number of HPV types to be in the region of 400 (Bzhalava et al., 2015). Since the transfer of 
the HPV reference laboratory from the DFKZ to the International HPV Reference Centre in 
Karolinska  Sweden in 2012, a total of 55 novel HPV types have attained number designation 
status, bringing the highest number to HPV226 (Latsuzbaia et al., 2018). And since 2014, 23 
novel types have been established, 19 (82.6%) of which belong to the Gamma genus (Mühr et 
al., 2018). Essentially, there are 221 HPV types due to a re-classification of 4 previously known 
types i.e. HPV46 reclassified as HPV20, HPV55 as HPV44, HPV64 as HPV34 and HPV79 
replaced by HPV91 (Terai and Burk, 2002) as these did not meet the updated criteria as 
unique HPV types. The 221 HPV types fall in to 5 different genera: Alpha (65 types), Beta (54 
types), Gamma (98 types), Mu (3 types) and Nu (1 type). 
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We report in the second chapter of this thesis the discovery and characterisation of ten novel 
Gammapapillomaviruses (Gamma-HPVs) and thus adding to the list of the ever-expanding 
genus. The addition of more PV sequences has a bearing on the understanding of the origin, 
evolution and clinical outcome prediction of given PV genomes. The proposition to include the 
four backbone ORFs that all PVs possess (E1, E2, L1 and L2) in the re-classification of PVs, will 
be discussed briefly in the same chapter.  
1.2 PAPILLOMAVIRUS STRUCTURE AND GENOME ORGANISATION 
 Structure: PV particles all share a similar non-enveloped icosahedral structure (50-60 nm in 
diameter) irrespective of genus (Doorbar et al., 2015). The structure of the virus coat 
consists of 360 molecules of L1 arranged into 72 capsomers, each capsomer is made up of 5 
L1 molecules (Schiller and Lowy, 2012, Modis et al., 2002, Chen et al., 2000, Hagensee et al., 
1994).  Capsomers interact through disulphide bonds at the C-terminal ends of the L1 
protein (Wolf et al., 2010, Schiller and Lowy, 2012) [Figure 1.2]. Therefore, each virion is 
composed of an outer shell of 72 capsomers comprising 60 hexameric and 12 pentameric 
capsomers of the major capsid protein (L1) arranged on a T=7 dextrose lattice (Zhou et al., 
1993, Conway and Meyers, 2009). The T=7 lattice cannot be obtained for visualisation from 
in vitro cultures, instead a T=1 lattice (Figure 1.2) can be visualised. The T=7 lattice is the 
speculated whole structure of the virion particle from X-ray crystallographic extrapolations 
(Bishop et al., 2007), [Figure 1.3].  The minor capsid protein (L2) is arranged in the inner side 
of the virus particle under the L1 protein, it is between the L1 and L2 capsid proteins that 
the circular DNA is packaged as a mini-chromosome (Modis et al., 2002). Thus, the L1 and L2 
proteins form the overall capsid of the viral particle and antigenic differences in these have 
been shown between different HPV strains (Bordeaux et al., 2006, Carter et al., 2006).  
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Figure 1.2 HPV structure showing the L1 pentamers, taken from (Bishop et al., 2007). 
 
 
 
Figure 1.3 HPV structure showing the L1 in relation to L2 capsid proteins taken from 
(Hagensee et al., 1994). 
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PV virion particles contain variable numbers of L2 molecules, with only portions of the L2 
being exposed to the outer surface (Rubio et al., 2011, Liu et al., 1997). The major 
surface‐exposed protein is the L1, which comprises a series of hypervariable amino acid 
regions or loops that have diverged between different PV types, due to host immune 
selection pressure, with neutralising antibodies raised to one HPV type binding to distantly 
related types only poorly (Wang and Roden, 2013). This varied cross-protection has obvious 
practical consequences in vaccine development.  
Genome: The PV genomes comprise of double-stranded circles of approximately 8 kbp in 
size containing 9-10 ORFs.  The 8 most common genes are E1, E2, E4, E5, E6, E7, L1 and L2 
(Syrjanen, 2018). The key proteins encoded are either structural (L1 and L2) or are involved 
in DNA replication (E1 and E2), while the other proteins (E4, E5, E6 and E7) are not 
necessarily encoded by all PVs and are considered as evolutionary modifications (McBride, 
2017).  Due to the small size of the PV genome and in order to fulfil the requirements of 
viral replication and survival, the genome allows for double coding and alternative protein 
isoforms (http://pave.niaid.nih.gov/#home 24) which is achieved through gene splicing. The 
circular double-stranded DNA genome is organised into three major regions: (i) an upstream 
regulatory region (Li et al., 2012),  also known as the long control region (LCR),  that is the 
origin of replication and houses transcription factor-binding sites and regulates gene 
expression; (ii) an early region, encoding for six genes involved in various functions ranging 
from viral replication to cell transformation (E1, E2, E4, E5, E6, E7), and (iii) a late region, 
encoding for the L1 and L2 structural capsid proteins which self-assemble to yield the virion 
particle (Bravo and Felez-Sanchez, 2015). Betapapillomaviruses (Beta-HPVs) and Gamma-
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HPVs lack the E5 ORF, which in the Alphapapillomaviruses (Alpha-HPVs) genera is located 
downstream of the E2 ORF (Figure 1.4).  
 
 
Figure 1.4 HPV genomic organization of the high‐risk Alpha, Mu, and Beta and Gamma-
HPV genomes.  
 
 
 
 
 
 
Alpha Gamma 
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Although all share a common genetic organization, the size and position of the major ORFs 
can vary, with Beta, Gamma and Mu- HPV types lacking an E5 ORF. Adapted with 
amendments from PaVE database https://pave.niaid.nih.gov/ (accessed 27/12/2018). 
The E4 protein (whose role is in virus escape from the epithelial surface) shows the greatest 
sequence heterogeneity among different HPV types. This E4 heterogeneity is thought to 
reflect the different tissue tropisms, probably host specificity and transmission routes of 
different PVs (DiMaio and Petti, 2013, Doorbar, 2013).  Perhaps more surprisingly, given its 
importance in genome amplification, is the absence of the HPV E6 protein in other Gamma-
HPV species, which will be discussed in detail later. 
1.3 PAPILLOMAVIRUS  LIFE CYCLE AND REPLICATION 
The most widely studied model of HPV life cycle and replication is that of HPV16 due to its 
involvement in anogenital and other cancers (Forman et al., 2012). Although this may be 
applicable to other HPVs, differences do exist between types, species and genera. Described 
here is the life cycle of HPV16 representing that of high-risk HPV types (hrHPV), which are 
associated with malignancy. The low-risk PV types, which are rarely found in cancers, differ 
from high-risk types in a variety of ways ranging from genome content and organisation, to 
gene functionality to biological and biochemical activities (Egawa and Doorbar, 2017). Of the 
low-risk types, the Alpha low-risk types HPV11 (Goon et al., 2008) and HPV6 (Cornall et al., 
2013) have been studied, though not adequately. Of the Beta types, HPV5 and HPV8 have 
also been studied and associated with Epidermodysplasia verruciformis (EV) (Lazarczyk et 
al., 2009), while for the Gamma types there is very little information on their life cycle as 
they have not been shown to be associated with important cancers. 
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Figure 1.5 Function of the major genes of HPVs.  
HPV genome is divided into three major regions: the LCR, an early region encoding six genes 
(E1, E2, E4, E5, E6, E7) and a late region encoding for the L1 and L2 capsid proteins. Taken 
from (Taberna et al., 2017) . 
HPV cell entry: PV virions enter the basal keratinocytes either through abrasion, small 
wounds or hair follicles (Doorbar, 2005). It has been shown that heparin sulfate 
proteoglycans (HSPG) play a role in virion entry into cells through interacting with L1 capsid 
proteins (Schiller et al., 2010, Aksoy et al., 2017) [Figure 1.8]. Receptor binding mechanisms 
maybe dependant on the HPV type or the cell type being infected or that multiple receptor 
strategies maybe involved in a single infection (DiGiuseppe et al., 2017). Important to note is 
that with HPV, cell attachment and entry into basal keratinocytes are not the rate limiting 
steps to infection (Handisurya et al., 2012) because infection does not require an intact 
virion, the naked viral DNA is equally infective (Bravo and Felez-Sanchez, 2015). Several 
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studies have shown that HSPG are the not the sole receptors, but several other receptors 
have been identified through experiments done mainly using HPV16 (Selinka et al., 2007, 
Day et al., 2008). Among the proteins that have been shown to be involved in viral entry are: 
α6 and β4 integrins (Evander et al., 1997), tetraspanins CD63 and CD151 (Spoden et al., 
2008), annexin A2 heterotetramer (Woodham et al., 2012) and epidermal growth factor 
receptors/ Keratinocyte growth factor receptors (EGFR/KGFR) (Dziduszko and Ozbun, 2013).  
Upon cell binding, the virus needs to be internalised into the cells in order to deliver the 
DNA to the host nucleus for a productive infection (Aksoy et al., 2017). There are two well 
described pathways for endocytosis namely the clathrin and caveolin pathway, all common 
among non-enveloped viruses (Pelkmans and Helenius, 2003). The mechanism of 
endocytosis used by both pathways is based on dynamin (a guanine triphosphatase enzyme 
responsible for endocytosis in eukaryotic cells),  which through its hydrolase activity pinches 
off endocytic vesicles from the plasma membrane (Aksoy et al., 2017). Work done using 
HPV16 endocytosis showed that it used the clathrin mediated endocytosis pathway (Smith 
et al., 2007) and it was later  also shown that both the clathrin and caveolin mediated 
pathways play a role in cell entry (Laniosz et al., 2009). There have not been any similar 
studies on other HPV genera save for Alpha-HPVs. 
Early phase of viral replication cycle: E1 and E2: The E1 protein contains three important 
domains, the ATP binding site, a bipartite nuclear localisation signal (NLS) and a nuclear 
export signal (NES). NES and NLS motifs are short sequence motifs (Table 1.1) which 
facilitate protein transport in and out of cell membranes (Bernhofer et al., 2018). NLS 
motifs vary in length but all share a simple consensus sequence K-K/R-X-K/R, and if the 
motif is a single one, it is a monopartite and if they are two it is bipartite (Bernhofer et 
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al., 2018), as shown for HPVs in the Table 1.1. The NES was first described in HIV-1 (Wen 
et al., 1995) and attempts to define a consensus sequence have been proposed but much 
variation was observed (la Cour et al., 2004). The classical NES motif however has 3-4 
hydrophobic amino acids especially leucine (Fischer et al., 1995). The ATP binding domain 
of the E1 is located in the C-terminus of the protein. The ATP binding domain is important 
for recruitment of E1 to the origin of replication in the LCR (Titolo et al., 1999). 
The E2 protein has two main domains: a NLS and DNA recognition helix. The NLS is as 
described in the E1 protein save that for E2, it is a monopartite domain in the 
transactivation domain as shown in Table 1.1. The DNA recognition helix of E2 is in the 
DNA binding domain as shown in Figure 1.6 below.  
 
Figure 1.6 Schematic presentation of the E2 domain structure.  
The transactivation domain- Light green; the DNA binding domain dark green; the hinge 
domain- gray wavy line. Taken from (Graham, 2016).  
 
PVs have acquired a unique ability to take advantage of the self-renewal process of 
stratified cutaneous and mucosal epithelia, as they replicate in synchronisation with 
epithelial differentiation from basal keratinocytes to stratum spinosium and to stratum 
granulosum (McBride, 2017). Viral replication is performed by high fidelity host DNA 
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polymerases in parallel with host DNA replication (Doorbar et al., 2012). Upon nuclear entry 
into the dividing epithelial cells, the first goal of the virus is to carry out the initial replication 
of its genome, this is achieved by replication and transcription factors of E1 and E2 (Graham, 
2017): the early expression of the viral transcription factor E1 allows for the regulation of 
early viral promoter to modulate expression of E6 and E7 regulatory proteins that ensures 
survival of HPV infected epithelial cells (Moody and Laimins, 2010). The interplay between 
E2 and E1, during early replication forms the basis of initial successful replication: the E2 
protein consists of two domains: a DNA binding domain and a protein binding domain linked 
together by a flexible hinge domain (van de Poel et al., 2018). The E2 forms a homodimer 
that can bind to four palindromic sites in the LCR with three of these sites situated next to 
the origin of replication and these three sites in the LCR are reserved for E1 mediated 
replication (McBride, 2013).  
Consequently, E2 binds E1 which in turn through a dimer of hexamers binds to the viral 
origin of replication in the LCR and thus activating cellular DNA replication machinery 
(McBride, 2017, Bergvall et al., 2013b). After this initial infection, incoming HPV genomes 
are replicated to produce around 50 to 100 episomal copies per cell, and this is the first 
phase of viral replication (Maglennon et al., 2011). The infected cell then leaves the basal 
layers and enters the transit enhancing proliferative layers of the epithelium where there is 
episomal and plasmid maintenance of virion particle numbers (Pinidis et al., 2016). In the 
infected basal cells, the HPV circular DNA is replicated parallel to the host DNA and in turn 
partitioned to daughter epithelial cells at differentiation. The partitioning into daughter cells 
is achieved through tethering (binding) of viral genomes to host cell chromosomes via E2 
that is bound to the LCR of the virus and other chromatin binding proteins (McBride, 2013). 
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The most widely studied anchor of viral genomes to host chromosomes is Bromodomain-
containing protein 4 (Brd4) that works in concert with E2 (Iftner et al., 2017), but many 
other alternative anchors have been studied. So HPV has mastered the art of carrying out its 
replication cycle in unison with epithelial cell differentiation and evading immune 
surveillance (Stanley, 2012), this is achieved through a series of a well-timed program of 
gene expression (Egawa et al., 2015).  
E4, E5, E6 and E7 protein activities during replication: The biological roles of E6 and E7 are 
essential in the early replication stages in the basal epithelial layers. The E6 and E7 proteins 
disrupt the checkpoint mechanisms of the cell cycle making sure all stages are completed 
properly, thus facilitating uncontrolled keratinocyte differentiation. PDZ proteins is a family 
of proteins containing the PDZ domain. PDZ is an abbreviation combining the first three 
proteins discovered to have the domain: post synaptic density protein (PSD95), Drosophila 
disc large tumour suppressor (Dlg1), and zonula occludens-1 protein (zo-1) (Kennedy, 1995). 
Binding to PDZ motifs is mediated by short peptide sequences referred to here as PDZ 
Binding Motif (PBM), usually located at the C-terminus of proteins (James and Roberts, 
2016). The PDZ domain-binding motif -X-(T/S)-X-(L/V) at the carboxy end of E6 is important 
for targeting PDZ proteins for proteasomal degradation, see Table 1.1. PBM binds to a whole 
range of other proteins giving E6 an essential role in viral life cycle and survival.  The E6 PBM 
is required for maintenance of episomal viral DNA and genome amplification usually in high 
risk HPVs (Delury et al., 2013). The E7 protein binds to pRB and degrades them resulting in 
cell cycle dysregulation (Roman and Munger, 2013a). The E6 protein also prevents apoptosis 
through its binding of p53 tumour suppressor (Martinez-Zapien et al., 2016).  
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The E6 protein is about 150 amino acids long and about 18 kDa (Bedard et al., 2008). The 
E6 has two main conserved domains, two Zinc fingers and a PBM (Miller et al., 2012) 
[figure 1.7A]. Zinc fingers are small structural protein motifs with finger-like protrusions, 
and Zinc finger domains are protein structures that contain multiple finger-like protrusions 
(Laity et al., 2001). Zinc finger domains are important structures in the synthesis of fusion 
protein complexes and serve a wide variety of biological functions (Roman and Munger, 
2013b). The E7 of most HPVs have one Zinc finger domain and may have a pRB binding 
domain (Figure 1.7B). The structure and function of the Zinc finger domain is as described 
for the E6. The pRB binding domain has a short peptide sequence signature (Table 1.1) as 
previously described, this domain is in part responsible for HPV carcinogenicity through 
its binding of the pRB (Roman and Munger, 2013a). 
HPV E5 proteins are small, transmembrane based and hydrophobic proteins spanning about 
40 to 93 amino acids in size (DiMaio and Petti, 2013). The E5 ORF is classified into four 
groups (alpha, beta, gamma and delta) based on clinical manifestation, particularly 
oncogenic potential (Bravo and Alonso, 2004a, Schiffman et al., 2005b). High risk HPVs 
encode the E5-alpha while E5-gamma and delta are encoded for by low risk HPVs (Garcia-
Vallve et al., 2005). 
As previously alluded to, the E5 is absent in many HPV genomes and hence pointing to the 
fact that it is not essential for the HPV life cycle but gives Alpha-PVs an added advantage to 
favour infection and transformation (Venuti et al., 2011). The E5 protein favours the 
overgrowth and prevents apoptosis of infected cells and hence induces malignant 
progression (DiMaio and Petti, 2013). E5 also helps the virus in evading immune response 
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through repression of major histocompatibility complex (MHC) presentation of viral 
peptides  
(Ashrafi et al., 2006). The transforming activity of the E5 has been demonstrated in various 
cell types (Ghai et al., 1996, Rho et al., 1996). Experiments with HPV6 provided the first 
evidence of E5 transforming activity in mammalian cells where it was shown that the 
expression of HPV6 E5 led to the anchorage and independent growth of murine fibroblasts 
(Chen and Mounts, 1990). Subsequently, it was also shown that HPV16 E5 induces 
anchorage and independent growth of murine keratinocytes and fibroblasts (Leechanachai 
et al., 1992, Pim et al., 1992). Thus, HPV E5 proteins are not strongly carcinogenic and not 
directly important for carcinogenesis because they are not always found in HPV associated 
tumours (Venuti et al., 2011).
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Figure 1.7  (A) Diagrammatic representation of HPV16 E6 showing the position of amino 
acid motifs that are important for protein integrity and function. (B) Diagrammatic 
representation of E7 and the most important amino acid motifs required for integrity 
and protein functions. 
(A) The two Zinc finger binding domains are shown, and regions that are involved in 
interacting with some of its cellular target proteins. The PDZ Binding Motif (PBM) is 
shown and the PKA phosphorylation site is also indicated; (B) One Zinc finger binding 
domain is shown, and the pRB binding (LXCXE) and the two serine residues (31 and 32) 
that are susceptible to casein kinase II (CKII) phosphorylation. Adapted with modifications 
from (Tomaić, 2016). 
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The HPV E4 ORF is within the E2 ORF, at about the central portion of the E2 gene within the 
flexible hinge region encoding domain (Doorbar, 2013). The main E4 gene product, E1^E4, is 
a spliced mRNA with a start codon in the E1 ORF (donor) and the acceptor site in the E2 ORF 
(Doorbar, 2013). One of the key functions of E4 in mucosal infections is its ability to 
restructure cytokeratin filaments in the later stages of the cycle, disrupting their structure 
and facilitating virion release from host cells (Wang et al., 2004, Doorbar et al., 1991). In 
cutaneous infections caused by HPV1 and HPV63 (Mu genus), HPV4 and 65 (Gamma genus) 
and HPV5 and 8 (Beta genus), the E4 protein is responsible for the formation of cytoplasmic 
inclusion granules that are characteristic of these infections (EGAWA, 1994, Peh et al., 
2002). The great abundance of E4 in cutaneous lesions is linked to these inclusion bodies 
(Doorbar et al., 1996), and have been found mostly in cells supporting vegetative viral 
genome amplification (Roberts et al., 2003). 
L1 and L2 activities during late phase of viral replication: The late phase of the viral 
replication involves increased production of viral copy numbers of copies per cell. In the 
upper epithelial layers, viral gene expression shifts to structural proteins, the L1 and L2, in 
order to promote virion assembly (Cerqueira and Schiller, 2017). The life cycle of PVs is 
heavily linked to differentiation of epithelial cells to which they are obligate pathogens, thus 
making the investigation of many aspects of  PV biology difficult to study (Cerqueira and 
Schiller, 2017) [Figure 1.8].  
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Figure 1.8 HPV Life Cycle and Replication.  
Taken from (Roden and Stern, 2018). HPV infection involves the binding of the virus to 
heparin sulfate proteoglycans (HSPGs) on the basement membrane (BM) through the 
major capsid protein L1. This is ensued by virus entry into the target basal keratinocyte. 
Several entry pathways have been proposed, none of which are necessarily independent 
of the other. In the infected basal cells, the viral genome replicates and establishes ∼50 
HPV copies, which then segregate between the daughter progeny as the cells undergo 
cell division. The early viral proteins, E6 and E7, are essential in stimulating the continued 
growth and environment for E1 and E2-driven vegetative viral genome replication to a 
very high copy number. Differentiation of infected cells in the upper epithelial layers 
stimulates the expression of E4 and then L1 and L2 to package the high copy numbers of 
the viral genome. The virions are released as E4 disintegrates the cytokeratin filaments, 
and the keratinocyte remains are removed from the epithelial surface. The viral life cycle 
is accomplished with minimal cell death and without peripheral viraemia or apparent 
inflammation, and thus evading local immune responses. 
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The L2 ORF contains early polyadenylation sites, which are positioned in the L2 ORF at the 5’ 
end or the N-terminal, are adenine rich and their function is to process early viral mRNA 
transcripts see Table 1.1. The late polyadenylation sites are usually downstream of the L1 
ORF within the LCR. Polyadenylation sites usually have this signature -AATAAA- (Chen et al., 
2007a, Chen et al., 2007b, Ure and Forslund, 2014a, Bottalico et al., 2012, Ostrbenk et al., 
2015). The N-terminal of the L2 protein contains a conserved furin cleavage motif (R-X-K/R-
R) see Table 1.1. Cleavage of the L2 protein by cellular protease results in viral capsid 
structural changes resulting in translocation of the viral particles into the host epithelia to 
deliver and integrate viral DNA into host genome (Ostrbenk et al., 2015). It has recently 
been described that a transmembrane domain at the N-terminal of the L2 minor capsid 
protein is essential for translocation of viral DNA across phospholipid bilayer membranes 
(Bronnimann et al., 2013, Wang and Roden, 2013) see Table 1.1. The domain consists of 
GxxxG motifs and similar glycine zipper GxxxGxxxG motifs that together work in unison to 
facilitate packing of DNA helices to pass lipid bilayers. The same NLS signal motifs in E1 and 
E2 have also been identified in the C-terminus of the L1 and L2 proteins as described 
elsewhere (Zhou et al., 1991, Nelson et al., 2000) see Table 1.1. 
Functions of the LCR during life cycle and replication: The LCR, with no ORFs, encompasses 
roughly 10% of the genome of most PVs (Bernard, 2013a). The LCR of different HPV types 
contains varying numbers of palindromic E2 binding sites (ACC-N6-GGT) (Brancaccio et al., 
2017) see Table 1.1. A palindromic sequence is a nucleotide sequence on a double-
stranded DNA where the 5' to 3' forward reading frame on one strand is identical to the 
sequence reading backward 5' to 3' on the complementary strand. The LCR also has a TATA-
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binding protein domain (Brancaccio et al., 2017). The TATA-binding protein (TBP) is a  
transcription factor that binds  to a DNA sequence called the TATA box see Table 1.1, and is 
important in pre-transcription during viral replication (Bernard, 2013a). 
The LCR is involved in regulation of early gene transcription through its interaction with 
cellular transcriptional factors (Sichero et al., 2013). Some of these transcriptional factors 
include NF1, API, Oct-1, Tef-1, Tef-2, YY1, TFIID and C/EBP. 
NF-1 sites: The NF1 plays a role in transcription during carcinogenesis. It was originally 
identified in the adenovirus genome where it binds to TTGGC(N)6CCAA but in PVs it binds to 
the half-site non-palindromic TTGGC (Bernard, 2013b).  
AP-1: The AP-1 site has been widely studied, its principal function is in viral gene expression 
and it has been suggested as the principal activator of all activators. The typical AP-1 binding 
site is the TGANTCA sequence. Major variations from this sequence have been known to 
also bind T (G/T)A/T)NT(A/C)A, making it impossible to predict AP-1 binding sites by mere 
sequence inspection, functional assays are a necessity (Bernard, 2013b).   
Oct-1: Octamer-1 is a member of the POU (Pit, Oct and Unc). Oct-1 has been shown to 
regulate a number of viral and cellular genes. The POU family possess a similar bipartite 
DNA binding sequence. The Oct -1 binds specifically to an ATGCAAAT sequence.  It has also 
been shown to bind very divergent factors making it difficult to use sequence inspection to 
identify these binding sites (Tantin, 2013, Bernard, 2013b). 
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1.4 PAPILLOMAVIRUS  CONSERVED DOMAINS AND MOTIFS 
According to the NCBI Conserved domains database (CDD) definition, conserved domains 
are evolutionary distinct functional and/or structural units of a protein (Fong and 
Marchler-Bauer, 2008). Domains are often identified by repeated (sequence or structure) 
units, which may vary in different contexts. Conserved domains contain maintained 
sequence patterns or motifs, which enable their identification in polypeptide sequences. 
Table 1.1 contains a description of each HPV protein and the conserved domains found in 
them. 
We report in the third chapter of this thesis on the different HPV conserved domains that 
were found in the ten novel Gamma-HPV types. However, the functions of these observed 
domains are beyond the scope of this thesis as the focus was on the identification and 
recognition of known conserved sequences.  
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Table 1. 1 PVs Conserved domains and motif sequence patterns.  
 
Gene/ 
Protein 
 
Domain 
 
Motif consensus sequences 
 
Reference 
E6 GATA Type Zinc 
fingers 
CxxC(x)29CxxC (Ostrbenk et al., 2015) 
PDZ binding domain x(T/S)x(L/V) (James and Roberts, 2016, Miller et al., 2012, Songyang et al., 1997) 
E7 E7 Conserved region 
1 
  (Wise-Draper and Wells, 2008) 
GATA Type Zinc 
fingers 
CxxC(x)29CxxC (Ostrbenk et al., 2015) 
pRB binding domain LxCxE  (McLaughlin-Drubin and Munger, 2009a, Mitsuishi et al., 2013, Ure and 
Forslund, 2014a) 
E1 
 
ATP binding site G(X)4GK(T/S) (Titolo et al., 1999) 
Bipartite nuclear 
localisation signal 
KRK and KRRL (Bernhofer et al., 2018, Zhou et al., 1991, Nelson et al., 2000, 
Ostrbenk et al., 2015) 
Nuclear export 
domain putative 
(L/I)(x)2-3(L/I)xx(L/I/V)x(L/I/V) (Fischer et al., 1995, Bergvall et al., 2013b) 
 
E2 
DNA recognition 
helix 
GxxNxLKCxRxR(x)8 (Graham, 2016) 
Nuclear localisation 
domain 
RKRxR/KRRR/KRXR (Bernhofer et al., 2018, Zhou et al., 1991, Nelson et al., 2000, Zou et 
al., 2000) 
L1 Nuclear localisation 
like domain 
K(K/R)R(K/R) (Bernhofer et al., 2018, Zhou et al., 1991, Nelson et al., 2000)  
L2 Nuclear localisation 
like domain 
(K/R)3R(K/R) (Bernhofer et al., 2018, Zhou et al., 1991, Nelson et al., 2000)  
Transmembrane 
binding domain 
G(x)3G(x)3G (Bronnimann et al., 2013, Wang and Roden, 2013) 
Furin cleavage site Rx(K/R)R (Ostrbenk et al., 2015) 
Early polyadenylation 
site 
AAT(A)3 (Chen et al., 2007a, Chen et al., 2007b, Ure and Forslund, 2014a, 
Bottalico et al., 2012, Ostrbenk et al., 2015) 
LCR E2 binding sites  ACC(N)6GGT (Androphy et al., 1987, Hirochika et al., 1988, Li et al., 1989, Võsa et al., 
2012) 
TATA binding box  TAT(A)
3
 (Bernard, 2013a) 
Late polyadenylation 
site 
AAT(A)
3
 (Chen et al., 2007a, Chen et al., 2007b, Ure and Forslund, 2014a, 
Bottalico et al., 2012, Ostrbenk et al., 2015) 
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1.5 EVOLUTIONARY DYNAMICS OF PAPILLOMAVIRUSES  
PVs are thought to evolve slowly because they hijack host cellular high-fidelity DNA 
polymerases with proofreading activity for replication (with an error rate of about 4.3 x 10-5 
substitutions per year (Korona et al., 2011)). Hence, it is generally assumed that PVs have 
co-evolved with their hosts (Bravo and Felez-Sanchez, 2015, Chen et al., 2009, Dube 
Mandishora et al., 2018). However, several host factors may affect PV evolutionary rates 
over time; for example the cellular protein APOBEC3 cytidine deaminase may result in 
codon usage biases in C>>T substitutions, selection pressures due to cellular or humoral 
immune responses may differ between genes and result in these genes displaying different 
substitution rates, or the cellular polymerases of different host species may differ in their 
degree of fidelity and proofreading activity such that virus lineages infecting different hosts 
might display different substitution rates (de Oliveira et al., 2015). Different PV genes have 
been shown to have different evolutionary rates, from an overall rate of 1.95 x10-8 and a 
range of 1.76 x10-8 to 2.69 x 10-8 substitutions/site/year (Van Doorslaer, 2013). The PV 
genome has modular nature, which is evident today in the different evolutionary rates of 
the different genes, the new genes E5, E6 and E7 encoding oncoproteins diverge faster than 
the old four genes E1, E2, L2 and L1 (García-Vallvé et al., 2005). The four old proteins are by 
themselves able to fulfil the basic tasks of replication, regulation, stabilisation and viral DNA 
packaging leading to vegetative release of viral progeny from host cells (Longworth and 
Laimins, 2004). The acquisition of the new oncogenes has introduced two PV phylogenies, 
high risk Alpha-PVs cluster together according to the phylogeny of these oncogenes (E5, E6, 
E7) but they do not cluster together according to the phylogeny of the capsid proteins (L1 
and L2) (Bravo and Alonso, 2004b). Additionally, the number of mutations are higher in the 
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new oncogenes than in most of the PV genes (Bravo and Alonso, 2004b). It is thus proposed 
that the history of PVs took place in different stages, the first stage represents the initial 
appearance of a prototype-PV with the cardinal genes (E1, E2, L2 and L1) found in all PVs. 
Then second stage involved further divergent evolutionary processes that led to the 
acquisition of the E5, E6 and E7 oncoproteins, and these newly acquired proteins evolved 
about twice faster than the core region of the genome (Garcia-Vallve et al., 2005). This is 
proposed to have occurred about 150 million years ago. The rapid diversification of the PVs 
is obvious from the star-like appearance of the PV phylogenetic tree (Garcia-Vallve et al., 
2005). It has been estimated that PVs appeared about 250-150 million years ago (Smelov et 
al.) Smelov et al. (2018)  in the Mesozoic Age (Age of reptiles/dinosaurs) (Bravo and Felez-
Sanchez, 2015) [Figure 1.9], whereas the most recent common ancestor (MRCA) of the 
Alpha, Beta, Gamma, Mu and Nu HPVs is predicted to have existed around 30-50 MYA in the 
Cenozoic Age (Age of mammals) (Chen et al., 2007b) (refer to Figure 1.10).  Further, the 
MRCA of the present-day Gamma-HPVs is predicted to have existed about 15-30 MYA (Chen 
et al., 2007b). The recent determination of new distinct PVs using next generation 
sequencing methods has begun to shed light on the evolutionary history of this virus family. 
However, the evolutionary history is complicated by both inter-gene phylogenetic 
incongruence and intra-gene variations (Van Doorslaer, 2013).  
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Figure 1.9 Global scenario of PV evolution.  
A) Ancestral tetrapod vertebrates were already infected by ancestral PVs. The four PV main 
groups (labelled in red, green, blue and orange) appeared during the evolution of sweat 
glands and hairs (250–150 MYA). Ensuing mammalian diversification triggered a further 
second phase of PV diversification (110-60 MYA) (Bravo and Felez-Sanchez, 2015).  
It has been observed that the genes and encoded amino acid sequences of viral early and 
late proteins have evolved differently in terms of evolutionary rate and selection pressure 
(Harari et al., 2014, García-Vallvé et al., 2005), and hence the incongruence between early 
and late trees. PV recombination events may provide a clue to the phylogenetic 
incongruence, but recombination is not the only explanation for this incongruence.  The 
study of PV recombination has mainly been hampered by limited recombination detection 
methods, mainly due to technical difficulties associated with the accurate alignment of 
highly diverse PV gene sequences prior to analysis, misaligned regions of sequences can be 
mistakenly be identified as recombination origins (Bolatti et al., 2016). 
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Figure 1. 10 Time calibrated phylogenetic tree of Gamma-HPVs.  
Classification based on (Bernard et al., 2010). The asterisk (*) indicates that some members 
of this clade have not yet been officially recognized as members of the Gamma-HPVs genus. 
The Gamma-6 species is highlighted in red. The scale bar indicates millions of years before 
the present. The Gamma-HPV  genus tree was rooted on CPV2 (Van Doorslaer and McBride, 
2016). Note: the Paleogene and Neogene Ages are Sub-ages of the Cenozoic. 
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The biological plausibility of HPV recombination is occasioned by the plurality of HPVs and 
the high frequencies of  observed HPV co-infections (Angulo and Carvajal-Rodriguez, 2007). 
Since the emergence of the AIDS pandemic, AIDS patients have been infected with diverse 
and multiple HPV types.  It is expected that this environment facilitates the emergence of 
HPV recombinants with somewhat new pathogenic characteristics (Varsani et al., 2006). 
However, there have been very few studies done on PV recombination, due to lack of 
proper detection methods until the year 2000, when the Recombination detection program 
(RDP) method was published by Martin and Rybicki (Martin and Rybicki, 2000), and 
subsequent versions of the same method in 2005 (Martin et al., 2005a, Martin et al., 
2005b). Even after the development of the RDP detection method, very few studies on PV 
recombination have been published, for Alpha-PVs (Narechania et al., 2005b, Ronco et al., 
2014),  Gamma-PVs (Bolatti et al., 2016, Varsani et al., 2006) and Beta-PVs (Varsani et al., 
2006). The Mu and Nu genera have very few PV types to study recombination unless the 
current efforts to discover novel HPVs using next generation sequencing are stepped up. 
However, Shah et al.  have proposed that inter-genus recombination of Alpha, Beta and 
Gamma-PVs might have occurred in primates (Shah et al., 2010).  
The evolutionary scenario of PVs remains unresolved and it will take more novel types to be 
discovered and an increment in the number of PV sequences before a conclusive 
understanding of the origin and adaptive radiation of PVs is completely understood. So far it 
is widely agreed that these viruses are evolutionarily static, diverge slowly, have strict tissue 
tropism, are host specific and that there are no recombination events (Van Doorslaer, 2013). 
It is further assumed that a primary adaptive radiation event of PVs led to the emergence of 
the first main lineages, and a second adaptive radiation of the main lineages and host 
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expansion led to species specificity. The third radiation occurred with the emergence of the 
E5 oncoprotein giving rise three viral lineages (Alpha,  Mu and Nu) (Willemsen and Bravo, 
2018). 
We report in the third chapter of this thesis on the investigation of recombination events 
among ten novel HPV types HPV211-HPV216 and HPV219-HPV222 (Murahwa et al., 2018) 
aligned together with all currently known members of the Gamma-HPVs genus and the use 
of phylogenetic tree incongruence tests to verify or disprove recombination. We also report 
on divergence times of the ten novel Gamma-HPVs from the MRCA and attempt to provide 
an evolutionary pathway and mechanism.  Understanding the mechanism and way PVs 
evolved will further clarify the correlation between a given genome and the phenotype and 
eventually the resulting clinical viral infection. 
1.6 HPV AND CANCER EPIDEMIOLOGY   
HPVs are the most commonly implicated viruses in a number of human malignancies with 
4.5% of all cancers worldwide (with an incidence of 630 000 cases per year) being 
attributable to HPV infection: 8.6% in women and 0.8% in men (de Martel, 2017). 
HPV‐related cancers account for 38,000 cases of which 21,000 are oropharyngeal cancers 
occurring in more developed countries, and the relative contributions of HPV16/18 and 
HPV6/11/16/18/31/33/45/52/58 are 73% and 90%, respectively (de Martel, 2017) [Figure 
1.11].  Involvement of HPV in cervical, penile, oral, genital, and oropharyngeal cancers and 
cutaneous lesions such as skin warts, squamous cell carcinomas, and basal cell carcinomas 
has been extensively documented (Murahwa et al., 2014, Bouwes Bavinck et al., 2010, 
Giuliano et al., 2008, Munger, 2002). Epidemiological surveys have documented extensively 
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the association between HPV and non-melanoma skin cancers (Bouwes Bavinck et al., 2010, 
Zakrzewska et al., 2012, Iannacone et al., 2013). The involvement of HPV in infections and 
cancer in a population with a high burden of HIV and AIDS is of great public health concern. 
 
 Table 1. 2 International Agency for Research on Cancer Risk classification of HPVs 
Classification HPV types 
Group 1 Carcinogenic (high-risk) 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 
Group 2A Probably carcinogenic (high-risk) 68 
Group 2B Possibly carcinogenic (intermediate risk) 26, 53, 66 a, 67, 70, 73, 82 
Beta-HPV types implicated in EV disease 
HPV5 and HPV8 
Group 2B Unknown risk b 30, 34, 69, 85, 86, 97 
Group 3 Low-risk 6, 11, 40, 42, 43, 44, 54, 61, 71, 72, 81, 89, 90 c 
HPVs of the Beta genus except types 5 and 8  
Not included in IARC 2012 classification (unknown risk/low- risk) HPV 74, 83, 87, 91 
Adapted from (Meisal et al., 2017) 
a-Classified as carcinogenic (high-risk) in IARC 2007 
b-Classified in this group based on their phylogenetic analogy to HPV types with sufficient or 
limited evidence of carcinogenicity. 
c-Not specified in IARC 2012. 
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HPVs, that are associated with malignant anogenital cancers, are found in the Alpha-PV 
genus and the International Agency for Research on Cancer 2007. (2007) defined twelve 
HPVs as 1A carcinogens and a thirteenth type as a 2A carcinogen (probably carcinogenic) 
(Meisal et al., 2017). Beta-PV infection is found in EV, a rare inherited disease associated 
with a high rate of skin cancer with the genus Beta- HPV types 5 and 8 classified by IARC as 
"possible carcinogenic" biological agents (group 2B) in EV disease (Smola, 2014) [Table 1.2]. 
A systematic review of case-control studies on cutaneous HPVs showed that several Beta-PV 
species were detected significantly more often in squamous cell carcinoma than among 
controls but these Beta-PVs have not yet accepted as the aetiological agent for these 
cancers (Bzhalava et al. 2013).  Although Beta-PVs have been regarded as “cutaneous” and 
not “mucosal” PVs, there is a report of anal Beta-PV infections being highly prevalent in the 
men who have sex with men (MSM) population and that Beta-PVs can establish persistent 
infection in the anal region for up to 4.8 years (Mlakar et al., 2014). 
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Figure 1.11 Age standardized world incidence rate (per 100 000) cancers linked to HPV, 
panel (a) anogenital cancers and (b) head and neck cancers (de Martel, 2017). 
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1.7 GAMMAPAPILLOMAVIRUSES AND CANCER 
Among all the HPVs, the genus Gamma-HPVs is the most diverse and fast growing with 27 
species and 98 officially recognised genotypes (Mühr et al., 2018) [Figure 1.12]. Gamma-HPVs 
appear to have broad epithelial tissue tropism with reported detection in cutaneous, mucosal 
and mucocutaneous sites (Ure and Forslund, 2014b, Ma et al., 2014b), including healthy skin 
(Antonsson et al., 2000), cutaneous lesions (Ekström et al., 2011), gut (Ma et al., 2014b), penis 
(Sichero et al., 2013, Sichero et al., 2014b), oral mucosa (Bottalico et al., 2011b), nasal mucosa 
(Forslund et al., 2013b), anal canal (Sichero et al., 2015b) and cervical mucosa (Meiring et al., 
2017) .  
These viruses have not been conclusively associated with any pathology or oncogenicity. A 
recent systematic review (Bzhalava et al., 2013) did however describe significantly elevated 
antibody levels in squamous cell carcinoma (SCC) cases infected with HPVs from the Gamma-1 
species. While Gamma-HPVs remain under-studied at a molecular level, a recent proteomic 
study of HPV197 demonstrated that the E6 and E7 proteins of this Gamma-HPV interact with 
several cellular targets including some of the important mediators of the oncogenic activities 
of high-risk E6 and E7 proteins (Grace and Munger, 2017). The E7 protein of Gamma-6 HPV108 
induces abnormal growth in organotypic keratinocyte cultures (Nobre et al., 2009b). The 
potential oncogenic activity of Gamma E6 and E7 proteins requires further investigation. 
Interestingly, HPVs in the Gamma-6 species do not encode E6 and E5 proteins (Ameur et al., 
2014a, Chen et al., 2007b). 
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Figure 1.12. Phylogenetic tree of members of the genus Gamma-HPVs. 
 
 37 
 
 Taken directly from ICTV website https://talk.ictvonline.org/ accessed 18/09/2018.  The E1, 
E2, L2, and L1 nucleotide sequences of 343 PV isolates including representatives of all species 
and genera within the Papillomaviridae family were aligned as amino acid sequences using 
MUSCLE v7.221. The JModeltest2 was used to determine the optimal model of evolution (GTR 
+ I + G) for the concatenated nucleotide sequences. Maximum likelihood (Mlakar et al.) trees 
were constructed using RAxML MPI v8.2.9 implementing the GTR substitution model. ML 
bootstrap analysis used the autoMRE-based stopping criterion in RAxML. Following tree 
construction (tree available in the Resources section of the Papillomaviridae Report), the 
subtree corresponding to the genus Gamma-HPVs was isolated. The tips are labelled with virus 
names and accession numbers; nodes are labelled with bootstrap support values (Simmonds 
et al., 2017). 
 
A recent study showed a high proportion of Gamma-HPVs in pre-cancerous cutaneous 
lesions of immunocompetent individuals, giving insights into the possible early role of these 
viruses in cutaneous malignancies (Bolatti et al., 2018). It was recently shown that Gamma-6 
HPVs or rather E6-minus viruses have acquired a 37 amino acid protein named E10, the ORF 
encoding this protein is upstream of the E7 start codon (Van Doorslaer and McBride, 2016, 
Van Doorslaer et al., 2017a). However, the acquisition of E10 does not likely compensate for 
all E6 functions. 
HPVs belonging to the Gamma-HPVs  have been always classified as cutaneous types (de 
Villiers, 2013). Recent evidence suggests a wider broader tissue tropism, with the 
cutaneotropic viruses being detected in muco-cutaneous areas of anogenital region, oral and 
nasal mucosa and genital lesions (Moscicki et al., 2017, Bottalico et al., 2011c, Foulongne et 
al., 2012, Ma et al., 2014a, Sichero et al., 2013, Forslund et al., 2013a, Tommasino, 2017).  
Our preliminary data shows that these viruses as well as Gamma-PVs are common in penile 
samples (Meiring et al., 2017).  There is a paucity of information on genital Beta- and 
Gamma-PVs in South African men or women, with only a few studies done (Meiring et al., 
2017, Ameur et al., 2014b). 
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1.8 HPV INFECTIONS IN MEN 
Globally HPV accounts for more than half of infection related cancers in women and about 
5% in men (Grce and Mravak-Stipetić, 2014, zur Hausen, 2009). As  a result of this high 
association between cervical cancer and HPV in women, men have not been primary focus 
for HPV research and intervention (Dunne et al., 2006). However, although a neglected field 
the HPV prevalence among men is high and not low (Rodriguez-Alvarez et al., 2018). The risk 
factors of HPV in men have been associated with sexual promiscuity, related to number of 
sexual partners (Nielson et al., 2009). Penile circumcision has been reported as a protective 
factor against HPV infection (Rositch et al., 2012). Firstly, the presence of a foreskin provides 
a moist environment that is favourable for HPV survival and facilitates virus entry. Second, 
the keratinisation of the circumcision scar can reduce HPV exposure and access to epidermal 
basal cells (Rositch et al., 2012, Olesen et al., 2017). Smoking has also been found to 
associated with HPV infection as cigarette smoke contains chemicals that disrupt the genetic 
intergrity of human cells which accelerates progression towards cancer in men (Rocha 
Rodríguez et al., 2012). Condom use is considered as partially protective against HPV 
infection (Lu et al., 2009, Repp et al., 2012, Vardas et al., 2011). Nielson et al. report that 
consistent condom use is associated with lower HPV prevalence in men (Nielson et al., 2007). 
Socio-economic factors have also been reported to have an impact in HPV infection among 
men, and among these are level of education (Lu et al., 2009). College and other forms of 
higher education were significantly associated with lower risk of acquiring new HPV 
infections (Lu et al., 2009). 
Based on current evidence, there is great benefit in vaccinating men against HPV (King et al., 
2015).  A study done in South Africa also reported on the benefits of vaccinating children in 
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order to reduce the burden of HPV related cancers such as anal and penile cancer in men 
(Muller et al., 2016).  
Racial and socio-cultural differences have been seen to be a factor in HPV acquisition, in a 
study by Akogbe et al. (Akogbe et al., 2012) (part of the multinational HIM study) the 
prevalence of any HPV infection and of oncogenic HPVs was lowest in Asian and Pacific 
Islanders, and this was attributed to their strict social behaviour associated with a 
conservative and restricted sexuality. There is limited data in Africa and particularly southern 
Africa in terms of HPV in men, and very little information on socio-economic and socio-
cultural factors in HPV acquisition. 
Anal HPV16  infection is known to be increased by the practice of anal sex which is common 
among men that have sex with men (MSM) and further amplified by HIV associated 
immunosuppression (Marra et al., 2018). It has been shown that anal cancer incidence is 
higher in MSM than in men who have sex with women (MSW) (Colon-Lopez et al., 2018, 
Silverberg et al., 2012), thus establishing HIV infection and sexual preference as independent 
determinants of anal HPV infection in men. The anogenital distribution and concordance of 
Beta- and Gamma-PV types in MSW and their partners have also been studied (Smelov et al., 
2018).  It was shown that there was a high concordance of Beta- and Gamma- -HPVs among 
sex partners although the etiological role, if any, in carcinogenesis was not clear.  
The presence of HPV DNA does not necessarily translate to presence of an infectious virus 
(Di Bonito et al., 2015), but more puzzling is the unclear transmission route of cutaneous 
Beta-and Gamma-HPVs into the anogenital area. It has been proposed that the presence of 
cutaneous HPV DNA in the anogenital area may be reflective of the deposition of viruses 
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released from other body parts with real infections (Sichero et al., 2013). Most of the recent 
information on HPV infection in men has been obtained from the HPV in men (HIM) multi-
centre study with over 4000 participants, which has described the prevalence of cutaneous 
HPV types among samples collected from external genital skin (foreskin etc.), anal canal and 
oral cavity from men (Bottalico et al., 2011a, Forslund et al., 2013c, Sichero et al., 2014a, 
Sichero et al., 2015a, Torres et al., 2015, Agalliu et al., 2016). 
In this thesis, the isolation of novel HPV types from penile swabs, from black South African 
men that had female sex partners, is described. The diversity of HPV viruses isolated from 
these swabs was vast as reported by Meiring et al (Meiring et al., 2017). 
1.9 MULTIPLE HPV INFECTIONS  
It has been reported that certain combinations of HPV types increase the risk of invasive 
cervical cancer (ICC) and pre-cancerous lesions when compared to infection with the 
individual HPV types (Carrillo-Garcia et al., 2014, Williamson, 2015).  The role of Beta- and 
Gamma-PVs in this process is unknown.  HIV-1 positive women have a higher prevalence of 
multiple HPV type infections in normal, premalignant lesions and ICC (Denny et al., 2014, 
Mbulawa et al., 2012).  HPV prevalence is very high in HIV-infected people, but generally 
only mucosal HPV types have been published on.  Our preliminary study indicates a higher 
prevalence of Beta- and Gamma-PVs in HIV-positive versus HIV-negative men from Cape 
Town (Meiring et al., 2017).  
1.10 HPV AND HIV CO-INFECTIONS  
The role of multiple HPV infections, including Beta- and Gamma-PVs on susceptibility to HIV 
is not well understood. There are a couple of studies indicating that people infected with 
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genital HPVs are at higher risk of acquiring HIV-1 than people who are not infected with HPV, 
even after adjusting for risk factors (Williamson, 2015).  In a meta-analysis HIV-1 incident 
infection was significantly associated with high-risk HPV infection in 5 of 6 studies (Lissouba 
et al., 2013). The mechanism for this increased susceptibility to HIV is not well understood.   
A study on Zimbabwean women showed that incident HIV-1 infection was directly linked to  
HPV clearance, suggesting that the immune response to HPV may result in an increase in 
cells prone to HIV infection in the genital tract.  HIV-1 acquisition was also linked to HPV 
clearance in a study on circumcised men, with increased HIV-1 acquisition being associated 
with number of HPV genotypes cleared (Tobian et al., 2013).  The same study showed that 
increased epidermal dendritic cell density was associated with HPV clearance and increased 
the risk of HIV-1 acquisition (Tobian et al., 2013). Thus, the immune response to HPV in 
mucosal tissue may result in an increase in the number of cells that are susceptible to HIV-1 
infection, and accordingly result in an increased incidence of HIV. 
1.11 HPV GENOMICS IN THE NEXT GENERATION SEQUENCING ERA 
Traditionally, the classification and description of novel viruses by the ICTV requires 
substantial biological information such as replication cycle, virion morphology, serology, host 
range, pathogenicity, epidemiology and nucleic acid sequence (Simmonds, 2015). However, 
next generation sequencing  (Van Doorslaer et al. (2017a) and metagenomic approaches 
pose a challenge to the virus classification landscape, with many viruses being known based 
on sequence data only (Simmonds et al., 2017). As of June 2016, the ICTV approved 
proposals to classify viruses solely on the basis of metagenomic sequence data, and a 
consensus statement released in the August of 2016 stated: “We believe that the time has 
come to advance the philosophy and practice of virus taxonomy by admitting viruses that are 
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identified only from metagenomics data as being bona fide viruses…” (Simmonds et al., 
2017). HPV classification based on next generation sequencing (NGS) data alone preceded 
that of many other virus families. Table 1.3 shows some of the most recent HPVs discovered 
by NGS methods and assigned HPV reference centre numbering but most are pending ICTV 
classification. It has been shown that rapid and accurate HPV genotyping for early cancer 
diagnosis can also be facilitated by NGS (Nilyanimit et al., 2018), as it detects HPV types that 
are not usually detected by routine genotyping methods. 
At the University of Cape Town (UCT), we have experience using next generation sequencing  
platforms to characterize HPVs from cervical samples and identify viruses that are not 
detected by commercial HPV typing kits (Ameur et al., 2014b, Meiring et al., 2012).  In the 
one study, 16 HPV genotypes were detected in a selected specimen using illumina 
sequencing. Four of the genotypes (HPV-30, 74, 86 and 90) detected were not included in 
the commercial kit. The prevalences of HPV-30, 74, 86 and 90 in 109 HIV positive South 
African women were found to be 14.6%, 12.8%, 4.6% and 8.3% respectively illustrating that 
these are not rare viruses in this population (Meiring et al., 2012). In the second study, a 
total of 46 different HPV types were found, many of which are not detected by existing 
genotyping assays and two novel HPVs identified by NGS in Cape Town were found to lack 
the E6 gene found in the majority of described HPVs (Ameur et al., 2014b).  
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 Table 1. 3 Recent novel HPVs discovered by Next generation sequencing. 
 
Author/date Novel HPV type Complete genome amplification-Cloning system Next Generation Sequencing Facility/Bioinformatics 
Hosnjak L et al. 2015 (Hosnjak et al., 2015) 179 and 184 Two overlapping amplicons-TOPO XL PCR Microsynth AG facility (Swiss) + primer 
walking/Vector NTI Advance-MEGA5 
Chouhy D et al. 2013 (Chouhy et al., 2013) 156 Two overlapping amplicons-pGEM T easy University of Maine facility (Araldi et al.)/MEGA5-
BEAST 
Mtsuishi T et al .2013 (Mitsuishi et al., 2013) 160 Single 8kb fragment-pBulescript II SK. Primer walking on AB/GENETYX-ClustalW-Bioedit-
MEGA 
Bottalico D et al. 2012 (Bottalico et al., 2012) 120 Two overlapping fragments-TOPO TA Microsynth AG facility (Swiss/MEGA5-MUSCLE-
RAxML 
Chen Z et al.2007 (Chen et al., 2007a) 101 and 103 Two overlapping fragments-pGEM T easy Einstein facility/ClustalX-Codon align-Mrbayes 
Ure AE et al. 2014 (Ure and Forslund, 2014b) 154 Four overlapping amplicons-TOPO TA MWG-Germany/UGENE-SMART-MUSCLE 
Arroyo S et al. 2014 (Arroyo Muhr et al., 2014) 197 Three overlapping fragments-TOPO PCR kit Miseq & Sanger/SOAPdenovo-Trinity-IDBA-UD 
assemblers 
Chen Z et al. 2007 (Chen et al., 2007a) 102 and 106 102-two overlapping fragments-pGEM T easy Einstein facility + primer walking/ClustalX-Codon 
align-Mrbayes 106 three overlapping fragments. 
Kovanda A et al. 201 1(Kovanda et al., 2011) 125 Single PCR fragment-reverse long-range PCR-Clone  
JET PCR Cloning 
Primer walking by ABI Prism/MEGA4-Bioedit 
Kocjan JB et al. 2013 (Kocjan et al., 2013b) 174 Single 8kb fragment-TOPO XL PCR Microsynth AG facility (Swiss)/Vector NTI Advance 
11. 
Bolatti M et al. 2017 (Bolatti et al., 2017) 209 Two overlapping fragments-TOPO TA and pGEM T easy University of Maine DNA sequencing facility 
Dutta S et al. 2017 (Dutta et al., 2017) 217 and 218 Single 8kb fragment -TOPO XL PCR cloning kit GATC Biotech, Germany 
Brancaccio et al. 2017 (Brancaccio et al., 2017a) 224 Single 8kb fragment -TOPO XL PCR cloning kit GATC Biotech, Germany 
Kocjan JB et al. 2013 (Kocjan et al., 2013a) 159 Two overlapping fragments-TOPO XL PCR Microsynth AG facility (Swiss)Vector NTI Advance-
MEGA5 
Latsuzbaia A et a.2018( Latsuzbaia et al., 2018)  226 Single 8kb fragment -TOPO XL PCR cloning kit Illumina Miniseq platform 
THIS STUDY (Murahwa et al., 2018) 211 , 212, 213, 214,  215, 216, 219, 220, 221, 
222 
Single 8kb fragment-pGEM T easy and TOPO XL PCR Illumina at Macrogen facility/ CLC main workbench 
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1.12 BACKGROUND DATA FOR THIS STUDY 
There are now more than 221 HPV types described with only the Alpha-PVs and a few Beta-
PVs being associated with cancers – the other two major genera infecting humans are the  
Beta- and Gamma-HPVs  (Arbyn et al., 2014) and very little is known about most of these 
types and their role in genital disease.  There are a number of publications studying Beta- 
and Gamma-HPVs in various skin cancers and pre-cancers but no firm association has been 
found because of the large variety of viruses detected (Ekstrom et al., 2013a).  Other studies 
have reported a large diversity of Beta-PVs in penile samples (Sichero et al., 2013), including 
penile carcinomas (del Pino et al., 2012) and genital warts (Bottalico et al., 2012). 
Our laboratory at UCT has stored genital samples collected from heterosexually active 
couples (Mbulawa et al., 2010).  These samples have been well characterised for mucosal 
HPV types detected by the Roche HPV Genotyping linear array test which detects 37 HPV 
types.  A study was done on 218 penile samples (104 HIV negative and 114 HIV positive) 
using high throughput sequencing (Roche 454) of amplimers (approximately 480 bp) 
obtained using FAP59/64 primers which have been designed to detect “cutaneous” or  Beta- 
and Gamma-PVs (Meiring et al., 2017) .  A total of 181 different HPVs were detected in 1330 
incidents of infection.   A total of 45 known Alpha-HPV types, 45 Beta-HPV types (34 known, 
10 putative and 1 novel putative), and 91 Gamma-HPV types (26 known, 51 putative and 14 
putative novel) were detected. Many HPV types (34.3%; 62/181) occurred only once in the 
penile samples, the majority of these belonged to the Gamma genus (44, 70.9%), followed 
by 16 (25.8%) Beta-HPVs and 2 (3.2%) Alpha-HPV types.  The most frequently detected 
Gamma-HPVs were HPV121 (6.9%), HPV101 (4.1%) and a novel putative HPV type, CT06 
(4.1%). In HIV-positive men types HPV121 (7.9%), HPV101 (6.1%) and CT02 (6.1%) and in 
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HIV-negative men types HPV121 (5.8%), HPV144 (4.8%), CT06 (3.8%) and CT04 (3.8%) were 
the most prevalent types. Of the 44 Gamma-HPVs detected in more than one sample, 28 
had higher prevalence in HIV-infected men. In total, there were 15 putative novel HPV types 
found with a prevalence varying between 0.5% to 4.1% of the men sampled (Meiring et al., 
2017).  The putative novel types L1 short fragments were deposited in Genbank under the 
following accession numbers (KY062999-KY063013) and were defined as those that had 
<90% identity to any known or previously described putative HPV. 
In this thesis, we report on the discovery, isolation, cloning, whole genome sequencing, 
characterisation, phylogeny and lastly the evolutionary dynamics inferred from 
incongruence, recombination and phylodynamic analysis (molecular divergence) of ten of 
the fifteen novel HPVs. 
1.13 JUSTIFICATION 
As more and more novel HPV types continue to be discovered worldwide, there is an 
increasing need to revisit archives of specimens stored and previously tested by first 
generation of molecular techniques to ascertain the full range of HPV types. Classification 
and assignment of novel HPVs to types or species can only be correctly achieved by whole 
genome sequencing. Thus, next generation sequencing technologies provide a powerful 
tool in attaining this goal. Ascertaining the new HPV types also provide essential 
information on the development of epitopes for future vaccines since full sequences for 
development of recombinant proteins will be known. 
Very little is known concerning Gamma-PVs in genital infections and there is paucity of 
information about these viruses in Africa.  This thesis focuses on the (i) genomics, (ii) intra-
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sample variation and (ii) evolutionary dynamics of ten novel Gamma-HPVs isolated from 
penile swabs in South Africa. 
1.14 AIMS AND OBJECTIVES 
1. The characterisation of potential novel HPVs from penile samples by complete 
genome sequencing and comparison to known HPVs. 
2. To identify and describe the conserved functional domains in the proteins of the 
novel HPV types. 
3. To study the phylogeny and genomic variation of the novel HPV types within 
samples. 
4. To explore the evolutionary dynamics of Gamma-PVs by analysing phylogenetic 
incongruence, recombination and phylodynamics (molecular divergence) in these 
viruses. 
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Chapter 2: Discovery, Characterisation and Genomic Variation of Ten Novel 
Gammapapillomavirus Types Isolated from Penile Swabs. 
2.0 INTRODUCTION  
In this chapter, we report on the discovery, genomic characterisation and phylogenetic 
evaluation of ten novel Gamma-HPV types: HPV211, HPV212, HPV213, HPV214, HPV215, 
HPV216, HPV219, HPV220, HPV221 and HPV222. These HPVs were previously identified in a 
study  that was done on 218 penile samples (104 HIV negative and 114 HIV positive) using 
high throughput sequencing (Roche 454) of amplimers obtained using FAP59/64 primers 
which were designed to detect “cutaneous” or Beta- and Gamma-HPVs (Forslund et al., 
1999). Fifteen putative novel HPV types were identified from the short HPV L1 FAP 
fragments HPV211 (CT02, KY063000), HPV212 (CT03, KY063001), HPV213 (CT04, KY063002), 
HPV214 (CT06, KY063004), HPV215 (CT07, KY063005), HPV216 (CT12, KY063010), HPV219 
(CT01, KY062999), HPV220 (CT08, KY063006), HPV221 (CT09, KY063007) and HPV222 (CT15 
KY063013) with a prevalence varying between 0.5% and 4.1% of men sampled (Meiring et 
al., 2017). We further examined variation of the novel types in clinical specimens from 
which they were identified.  
2.1 METHODS AND MATERIALS 
2.1.1 ETHICS STATEMENT 
Ethical approval for the study was granted by the Health Research Ethics Committee of UCT, 
Faculty of Health Sciences (HREC reference: 231/2015 and 258/2006). Written consent was 
obtained from all the study participants, after they consented to have their blood and 
genital swabs samples collected and the storage of their biological samples for future 
laboratory tests. 
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2.1.2 PENILE SAMPLES  
In 2007, samples were obtained from African black men who were participating in a 
heterosexual couples study on the natural history of HPV infection in South Africa (Mbulawa 
et al., 2009). Penile swab samples were obtained by dry swabbing of the penile shaft, glans 
and foreskin if present, using a Digene swab and stored at -80 °C in specimen transport 
medium (STM, Qiagen). The details of the original source participants from which the novel 
HPV types were isolated are given in Table 2.1. 
Table 2.1  Details of participants from which novel sequences were obtained. 
Sequence ID Isolate Age Isolation source 
HPV211 CT02 29 Penile swab from a South African HIV negative male 
HPV212 CT03 42 Penile swab from a South African HIV positive male 
HPV213 CT04 28 Penile swab from a South African HIV negative male 
HPV214 CT06 24 Penile swab from a South African HIV negative male 
HPV215 CT07 41 Penile swab from a South African HIV negative male 
HPV216 CT12 45 Penile swab from a South African HIV positive male 
HPV219 CT01 28 Penile swab from a South African HIV positive male 
HPV220 CT08 31 Penile swab from a South African HIV positive male 
HPV221 CT09 23 Penile swab from a South African HIV positive male 
HPV222 CT15 51 Penile swab from a South African HIV negative male 
 
2.1.3 NUCLEIC ACID ISOLATION AND AMPLIFICATION 
DNA was extracted using the MagNA Pure Compact Nucleic Acid Isolation kit (Roche, USA) 
and circular genomes enriched using the Illustra TempliPhi 100 Amplification kit (GE 
Healthcare, Amersham, UK). Rolling circle amplification was performed according to the 
manufacturer’s instructions, with initial denaturation at 95⁰C for 3 minutes and held at 4⁰C 
for 10 minutes before adding the buffer enzyme mix, followed by an 18-hour incubation at 
30⁰C and the reaction stopped by a 65⁰C incubation for 10 minutes. 
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2.1.4 COMPLETE GENOME AMPLIFICATION  
The complete genomes were amplified by PCR using primers (primer sequences are 
provided in Table 2.2), that annealed back to back allowing for the amplification of the 
whole genome as one amplicon. Primers were designed based on L1 FAP sequences from 
Meiring and co-workers (Meiring et al., 2017). Primer sets were designed in CLC main 
workbench (Qiagen). The partial L1 nucleotide sequences of HPV211, HPV212, HPV213, 
HPV214, HPV215, HPV216, HPV219, HPV220, HPV221 and HPV222 were originally identified 
as potentially novel in 2014 using FAP primers on penile samples from men enrolled in a 
cohort of heterosexual couple. 
Table 2.2 Novel HPV L1 back to back type specific primer sequences. 
HPV type Primer Sequences 
HPV211 
forward-GTTACGGGGAATTCAGATAGGTAGAGGTGG 
reverse- TTCCAAACCAGTCTTTCATGGTCAGAATTG 
HPV212 
forward- ATAGAAATAGGTAGAGGTGGGCCTTTAGG 
reverse-AGCTCGTAATTTCCAAACTAAGCGTTCG 
HPV213 
forward-TGGCAGTTACGGGGTGTTGAGGTAGAC 
reverse- CACAAGACGTTCCTCGTTGGGATCATAC 
HPV214 
forward-GCCTTTGGGTATTGGGTCTACTGGTCAC 
reverse-CCACCCCGTGCAATATCAATGCCACGTAAC 
HPV215 
forward- ATGGTTTGCAAATTGACAGAGGTGGTCC 
reverse- ATAATTTCCACACCAGCCTTTCATGTTGTG 
HPV216 
forward- CAACAGGTCATCCATTATTTGATCGCTTAC 
reverse- TTCCTATCCCTAGGGGACCACCTCTATC 
HPV219 
Forward- TAAGTTATCAGATACCGAAAACCCTTTGGCTC 
Reverse- TTTAATAAAGGATGTCCTGTAGCGCCAATACCC 
HPV220 
Forward- ATTGAGGTTGGCCGTGGTGGTC 
Reverse- GCCCCGTAGCCTCCATATTAAACGTTCG 
HPV221 
Forward- GTATAGAAATTCAAAGAGGGGGCCCATTAG 
Reverse- CTTTTAGTTTCCATACCAAGCGTTGGGTTTCTG 
HPV222 
Forward- CAACAAAATGGCCTTTGTCCTCC 
Reverse- TTGTTCCCCTGCACAAGGTAATGC 
 
The KAPA LongRange HotStart PCR kit (KAPA Biosystems, USA) was used to amplify the 
novel HPV genomes in a touch down PCR. Each reaction had 1X KAPA LongRange Buffer, 
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1.75 mM MgCl2, 0.3 mM of each dNTP, 0.675 U of the KAPA LongRange DNA polymerase, 0.5 
µM of each primer and nuclease free water. The PCR conditions were as follows: 94°C for 3 
min followed by 12 cycles of 25 sec at 94°C, 68°C (reduced by 2°C every 2 cycles) for 15 sec, 
and 7 min of extension at 68°C, followed by 20 cycles of 25 sec at 94°C, 56 °C for 15 sec and 
7 min at 68 °C. The final extension was performed at 72°C for 10 min. The PCR products 
were purified by gel electrophoresis before proceeding to cloning. For each of the novel HPV 
types, 2 sets of PCR reactions were done, in order to rule out PCR artefacts in the analysis of 
sequences. 
2.1.5 CLONING   
The resulting PCR products were gel purified using the MinElute gel extraction kit (Qiagen, 
Germany) and cloned into the pGEM-T Easy vector (Promega, USA) for HPV211-HPV216 and 
the TOPO XL vector (Thermo Fisher Scientific, USA) for HPV219-HPV222. Transformation 
was done in JM 109 E. coli chemically competent cells (Promega, USA). The cells were 
cultured on Luria broth agar plates containing 50 µg/ml of carbenicillin and incubated at 
37°C for 18 hours. Bacterial colonies with recombinant plasmids were selected by 
blue/white screening method using 5-Bromo-4-Chloro-3-Indolyl β-D-Galactopyranoside (X-
gal) treated LB agar plates. Ten colonies (ten clones) were selected to represent each of 
HPV211, HPV212, HPV213, HPV214, HPV215, HPV216, HPV219, HPV220, HPV221 and 
HPV222 (multiple separate clones of each type were generated in case errors had occurred 
during PCR amplification). The plasmid DNA of each of the ten clones was isolated from 
bacterial culture in 3 ml of LB broth containing carbenicillin using High Pure Plasmid 
Isolation kit (Roche, USA). Aliquots of the purified plasmid DNA were analysed by gel 
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electrophoresis and compared to a known pGEM-T Easy vector or TOPO XL Vector with HPV 
DNA fragment for confirmation.  
Successful cloning was also confirmed by Sanger sequencing of approximately 800 bp of the 
HPV plasmids at the insert and vector junction using an M13 reverse primer. Subsequent 
alignment of the sequenced fragments to the NCBI non-redundant nucleotide database 
using BLASTn (https://blast.ncbi.nlm.nih.gov/Blast.cgi) was done to verify that they were 
HPV sequences. 
2.1.6 LIBRARY PREPARATION AND SEQUENCING  
The purified plasmids were then prepared for next generation sequencing (Van Doorslaer et 
al.). Libraries were prepared using KAPA HyperPlus library preparation kit (KAPA Biosystems) 
which involved enzymatic fragmentation, end repair and A tailing, library amplification and a 
last clean up step using solid phase reversible immobilisation (SPRI) were done as described 
below.  
DNA from the plasmids was first quantified by a fluorometric method based using the 
Quanti-iT PicoGreen dsDNA assay kit (ThermoFisher, USA). Reactions for fragmentation, end 
repair, A tailing, adaptor ligation and post ligation clean up were set up as outlined below. 
The plasmids were first subjected to different fragmentation incubation times of 3, 5, 7 and 
10 minutes to determine an optimal incubation time that yielded DNA fragments in the 
range 550 to 600 bp. Analysis of the fragmented DNA from the varied time experiments 
were done using a bioanalyser (Agilent 2100 analyser). The optimal fragmentation time was 
determined to be 9 minutes, which gave about 550 bp to 600 bp fragment length. After 
fragmentation, the fragments were enzymatically end repaired and A-tailed to prepare 
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them for adaptor ligation. The DNA fragments were ligated to paired end (PE) Illumina 
adaptor sequences, index1 (i7) adaptors and index2 (i5) adaptors. Post-ligation clean-up was 
also done using SPRI on Agencourt AMPure XP beads (Beckman Coulter, USA). Post-library 
preparation and another quantification of the libraries were done using the Quanti-iT 
PicoGreen dsDNA assay kit (ThermoFisher, USA). Each library was pooled into one tube 
based on the determined concentrations. For HPV211-HPV216, 72 clones were multiplexed 
together into one Illumina library and for HPV219-HPV222, 68 clones were multiplexed into 
a second run. In total 140 clones were sequenced (Table 2.3). Sequencing was done using 
Illumina MiSeq 300 bp paired end sequencing at Macrogen in Korea (Seoul, South Korea). 
Each library was sequenced on a separate run. 
2.1.7 ILLUMINA DATA QUALITY CONTROL  
A total of 32,409,876 reads, with a median of 578,992 reads per sample (range: 352,306-
784,098) were obtained for each HPV plasmid. Illumina sequence reads were processed in 
CLC Genomic Workbench (Qiagen, Germany). Reads were trimmed using a quality score 
limit of 0.05 and any reads with more than 2 ambiguities discarded (Figure 2.2). De novo 
assembly of reads was done in CLC genomics. 
2.1.8 GENOMIC CHARACTERISATION AND PHYLOGENETIC ANALYSIS 
Sequence trimming, alignment and the de novo genome assembly was done in CLC Genomic 
Workbench (GW) v8.5.1 (Qiagen, USA). Genome lengths and nucleotide positions of the 
different ORFs were determined in CLC GW. The GC content was computed using an online 
tool (http://www.biologicscorp.com/tools/GCContent).  Multiple sequence alignments 
(MSAs) were done in CLC GW and Multiple Sequence Comparison by Log-Expectation 
 55 | P a g e  
 
(MUSCLE) (Edgar, 2004b). Variant, nucleotide and amino acid mismatches among clones of 
HPV212, HPV213, HPV215, HPV220 and HPV222 were analysed using nucleotide 
mismatches highlighter (Keele et al., 2008). Pairwise comparisons of variants of the same 
novel HPV type and for each putative novel HPV type with its most closely related known 
HPV, were also done in CLC GW.  
ORF prediction was done in CLC GW (Qiagen, Germany). The procedure to annotate the 
novel HPV genomes is illustrated in Figure 2. 1. The initial step was the prediction of all 
possible ORFs in the forward strand of each complete novel genome in CLC GW. A minimum 
ORF nucleotide length was set at 300 nucleotides. The predicted ORFs were then compared 
to those of the closest known HPV types as annotated in the PaVE (Papillomavirus Episteme) 
database. The potential ORFs were then translated and subjected to BLAST in NCBI protein 
database to check if they relate to the closest relative of the novel type. All the novel types 
were checked to have the backbone ORFs E1, E2, L1 and L2 encoded by all PVs, some HPVs 
lack E6 or E7 and most Gamma-HPVs have been shown to lack E5. A similar but not identical 
manual annotation has been described elsewhere (Van Doorslaer et al., 2013b). The final 
step was a multiple sequence alignment of all the homologous novel HPV proteins with that 
of their closest known relatives to check for expected length and identification of known 
conserved regions (Figure 2.1). The first position of the complete genomes of HPV211, 
HPV212, HPV213, HPV215, HPV216, HPV219, HPV220, HPV221 and HPV222 were set at the 
first ATG of the E6 ORF. For HPV214, the first position was set at the first ATG of the E7 ORF 
because it lacks the E6 ORF. E1^E4 and E2^E8  splice donor/acceptor sites  were predicted 
using manual inspection of splice sites predicted by NNSplice 0.9 (Reese et al., 1997), 
filtered using the set of criteria defined by Van Doorslaer and co-workers (Van Doorslaer et 
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al., 2017a). These criteria were the result of rigoroud comparative genomics among well 
known PVs. For example, the E4 portion of the E1∧E4 mRNA is derived from the +1 reading 
frame of E2. Similarly, the E8 fragment of the E8∧E2 protein is contained within the E1 +1 
frame.  E1∧E4 and E8∧E2 utilize the same splice acceptor site located within E2 (Van 
Doorslaer et al., 2017a). A checklist to ensure the spliced gene products were accurately 
predicted is outlined in Supplementary Table 2.9 in the appendix.  
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Figure 2.1 Genome annotation procedure. 
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Table 2.3 Summary of work done on the amplification, cloning, Sanger and Illumina sequencing of novel Gamma-HPV types. 
Original Putative 
Novel Type  
Closest HPV 
Match 
Genome 
amplified 
Genome 
cloned 
Number 
of clones 
generated 
Sanger 
sequence 
confirmation 
Illumina 
Miseq 
De novo 
assembly 
Final 
number of 
clones 
analysed 
Assigned HPV 
Reference Centre 
number 
CT01 HPV153   11    10 HPV219 
CT02 HPV168   11    11 HPV211 
CT03 HPV144   11    11 HPV212 
CT04 HPV153   10    10 HPV213 
CT05 HPV146   12    10 # 
CT06 HPV103   8    8 HPV214 
CT07 HPV129   8    8 HPV215 
CT08 HPV144   10    10 HPV220 
CT09  HPV142   10    10 HPV221 
CT10 HPV144   9    0 X 
CT11   HPV154   9  X X 0 X 
CT12 HPV129   11    11 HPV216 
CT13 HPV175 X X 0 X X X 0 X 
CT14 HPV101 X X 0 X X X 0 X 
CT15      HPV95   10    5 HPV222 
Fa101/Fa55/Fa91/SE55    20   X 0 X 
    150           140  104  
 
 X-Procedure was not successfully done or was not done due to an unsuccessful prior procedure. 
-Procedure successfully done. 
#-HPV type number had been previously assigned i.e. CT05 was not a novel HPV type 
Comments: In total 17 full genomes were successfully amplified using Long range PCR and these were also successfully cloned. A total of 150 clones 
were generated using p-GEM T easy and TOPO XL cloning systems, and 140 (72 in the first run and 68 in the second run) were selected for Illumina 
sequencing, 104 clones were finally analysed after trimming assembly and all quality checks.  
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2.1.9 CLONE SELECTION 
In order to select the most suitable clone for submission to the International HPV Reference 
Centre for purposes of nomenclature, multiple whole genome sequence alignments of the 
clones of each novel type were done in CLC genomics, where the reference sequence was 
the consensus of the clones. Mismatches between the different clones were identified using 
an online single nucleotide polymorphism (SNP) highlighter from Los Almos data base (Keele 
et al., 2008). Relatedness of the clones of the same novel HPV type was determined from 
the figures generated by comparing the positions of the mismatches along the whole 
genome. The clone with the highest percentage pairwise identity to the consensus sequence 
was treated as the prototype reference sequence. Chosen prototypes were carefully 
analysed and the ORFs annotated, translated into amino acids sequences and pairwise 
compared to the other clones of the closest known HPV types to verify they were the right 
clones. The prototype reference clones were sent to the International HPV Reference 
Centre, which assigned HPV numbers on verification of the sequence (HPV211 to HPV216 
and HPV219 to HPV222).  
2.1.10 NUCLEOTIDE ACCESSION NUMBERS 
The novel HPV DNA sequences of the prototypes were deposited in Genbank under the 
following accession numbers: HPV211 MF509816, HPV212 MF509817, HPV213 MF509818, 
HPV214 MF509819, HPV215 MF509820, and HPV216 MF509821. The GenBank accession 
numbers for HPV219, HPV220, HPV221, HPV222 genomes are MH172376, MH172377, 
MH172378, MH172379, respectively. 
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2.1.11 PHYLOGENETIC ANALYSIS 
For the phylogenetic analysis, L1 nucleotide sequences from HPV211-to HPV216 and 
HPV219 to HPV222 were aligned with L1 sequences from the PaVE database (Van Doorslaer 
et al., 2013a) using MUltiple Sequence Comparison by Log- Expectation (MUSCLE) (Edgar, 
2004a). A maximum likelihood tree was then generated with PhyML 3.0 (Guindon et al., 
2010) using the GTR+I+R substitution model, as determined by jmodeltest (Darriba et al., 
2012). The approximate likelihood ratio test (aLRT) was used to estimate branch support 
(Anisimova and Gascuel, 2006). The tree was visualised in Interactive tree of life (iTOL) 4.2.3  
(Letunic and Bork, 2016), an online tool for the display and annotation of phylogenetic and 
other trees.  
 2.1.12 NUCLEOTIDE AND AMINO ACID VARIATION 
Nucleotide and amino acid variations in novel HPV types that showed differences in the 
clones generated were determined from multiple sequence alignments of the clones of each 
novel type. The percentage nucleotide and amino acid substitutions was also determined 
for each ORF. The selection pressures acting on the coding sequences of the novel HPVs 
were estimated by calculating codon-specific non-synonymous (dN) and synonymous (dS) 
substitution rates using the Synonymous Non-synonymous Analysis Program (SNAP) version 
2.1.1 (Rodrigo, 2000) (http://www.hiv.lanl.gov/content/sequence/SNAP/SNAP.html). This 
program uses the unweighted pathway method of Nei-Gojobori (Nei and Gojobori, 1986) 
and the Jukes-Cantor model (Rodrigo, 2000). The dN/dS ratios were calculated, with a ratio 
of one indicating neutral selection, >1 diversifying positive selection and <1 negative or 
purifying selection (Chen et al., 2009). 
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2.1.13 IDENTIFICATION OF CONSERVED DOMAINS 
The amino acid sequences of each novel HPV protein were aligned to homologous amino 
acid and nucleotide sequences of the closest known HPV types. These multiple sequence 
alignments with homologous proteins were done in CLC main workbench. Manual 
inspection of the MSA was used to identify putative conserved domains in the novel HPV 
types. Manual inspection in combination with the knowledge of the position of conserved 
domains in homologous proteins of known HPV types was used to verify the putative 
conserved domains. The protein sequences were manually inspected for the motifs 
identified in the literature as shown in Table 1.1. 
2. 2 RESULTS 
2.2.1 GENOMIC ORGANISATION  
In this study ten novel HPVs were cloned into pGEM-T Easy vector/ TOPO XL vector and 
sequenced using Illumina MiSeq 300bp paired end sequencing. Eleven clones of HPV211, 
and another eleven of HPV212, ten clones of HPV213, eight clones of HPV214, eight of 
HPV215 and eleven of HPV216 were included in the first sequencing run. In the second run 
HPV219, HPV220 and HPV221 had ten clones each while HPV222 had 5 clones that were 
pooled for deep sequenced. Notnot all of the clones had useful sequences post-NGS 
especially after quality checks and trimming. The assembled sequences of the viral genomes 
revealed sizes ranging from 7096 bp for HPV213 to 7357 bp for HPV214 (Table 2.4). The ORF 
positions on the genome and sizes of the corresponding proteins are given in Table 2.4. The 
genomic organisation of HPV211, HPV213, HPV215, HPV216, HPV219 and HPV220 were 
typical of Gamma-HPVs, encoding five early (E1, E2, E4, E6 and E7) and two late (L1 and L2) 
proteins, and lacking the E5 gene. HPV212, HPV221 and HPV222 did not have an E4 start 
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codon as has been reported elsewhere (Li et al., 2012). The spliced E1^E4 transcript, that 
encodes the primary E4-gene product (Doorbar, 2013) was however identified in all ten 
genomes. HPV214 additionally lacked the ORF encoding the E6 protein but a putative ORF 
called E10, upstream of the E7 ORF (Figure 2.2) was identified (Van Doorslaer and McBride, 
2016, Van Doorslaer et al., 2017a). The genomic organisation for HPV214 and HPV220 are 
illustrated as examples in Figure 2.3. HPV220 resembles the typical Gamma-HPVs genome 
organization and HPV214 shows a lack of E6 ORF and the putative E10 ORF. 
 
Figure 2.2 Alignment of putative E10, (37amino acid protein) of HPV214 with the E10 
proteins of the most closely related HPV types from Gamma-6 species. 
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Figure 2.3 Examples of the genomic organization of the novel HPV types.  
A) HPV220 resembling the typical Gamma-HPVs genome organization and B) HPV214 showing lack of E6 ORF and the putativeE10 ORF.
 
 
A 
B 
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 Table 2.4 Genome lengths of novel HPV types and ORF positions on the genome and sizes of proteins. 
 
 
 
 
 
 
 
 
 
 
 
 
             
 
              # No E6 ORF            *start codon not determined 
  HPV211 HPV212 HPV213 HPV214 HPV215 HPV216 HPV219 HPV220 HPV221 HPV222 
Genome 
length (bp) 
7253 7208 7096 7357 7186 7233 7108 7381 7326 7275 
ORF position (Protein size in amino acids) 
E6 1-420 (140) 1-447 (149) 1-453 (151) # 1-438 (146) 1-459 (153) 1-435(145) 1-423(141) 1-432 (144) 1-423 (141) 
E7 417-707 (97) 444-743 (100) 422-715 
(98) 
1-303 (101) 440-733 
(98) 
462-755 
(98) 
422-715 
(98) 
420-719 
(100) 
434-727 (98) 420-710 (97) 
E1 694-2508 
(605) 
727-2526 
(600) 
702-2513 
(604) 
284-2188 
(635) 
717-2528 
(604) 
739-2550 
(604) 
702-2513 
(604) 
703-2511 
(603) 
714-2546 
(611) 
700-2502 (601) 
E2 2429-3619 
(397) 
2465-3628 
(388) 
2449-3624 
(392) 
2130-3296 
(389) 
2473-3624 
(384) 
2495-3667 
(391) 
2449-3621 
(391) 
2450-3616 
(389) 
2488-3672 
(395) 
2435-3631 (399) 
E4 2940-3380 
(147) 
*<3036-3386 
(117) 
2921-3397 
(159) 
2704-3057 
(118) 
2900-3391 
(164) 
2922-3434 
(171) 
2921-3385 
(154) 
2919-3371 
(151) 
*<3053-
3433 (127) 
<*3030-3389 (120) 
L2 3622-5220 
(533) 
3628-5154 
(509) 
3629-5122 
(498) 
3360-4973 
(538) 
3626-5137 
(504) 
3669-5186 
(506) 
3634-5127 
(498) 
3623-5224 
(534) 
3674-5245 
(524) 
3648-5180 (511) 
L1 5231-6781 
(517) 
5166-6719 
(518) 
5133-6659 
(509) 
4984-6519 
(512) 
5146-6696 
(517) 
5195-6748 
(518) 
5138-6664 
(509) 
5237-6781 
(515) 
5256-6818 
(521 ) 
5192-6730 (513) 
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2.2.2 CONSERVED DOMAINS ANALYSIS 
All the ten novel HPVs had Zinc finger Binding Domains in the E6 and E7 proteins. In the E6, 
there were two Zinc finger Binding Domains separated by 36 amino acids, with  
(CxxC(x)29CxxC) conserved sequence as described elsewhere (Latsuzbaia et al., 2018, 
Brancaccio et al., 2017, Dutta et al., 2017), except for HPV214 that did not have the E6 ORF.  
The E7 of all the novel types all had a single Zinc finger Binding Domain (Table 2.5).  
Putative PDZ binding domains were identified in the E6 N-terminal of all the novel types 
except for HPV212, HPV220, HPV221, HPV222 and HPV214 (which lacks the E6 protein). The 
classical x(T/S)x(L/V) PDZ motif (Table 2.5), has also been described elsewhere (Martin et al., 
2014, de Villiers and Gunst, 2009). 
The LxCxE consensus motif (Ostrbenk et al., 2015, Mitsuishi et al., 2013, Wang et al., 2010) 
essential for binding of pRB was present only in the E7 protein of HPV214 and HPV222 
(Table 2.4), this has also been described elsewhere (Dutta et al., 2017).  The E1 protein of all 
the novel types contained the ATP binding sites with the typical consensus motif 
G(x)4GK(T/S) in the C-terminus (Chen et al., 2007b, Latsuzbaia et al., 2018). NLS sites were 
identified in the E1, E2, L1 and L2 proteins of all the novel HPV types. The NLS sites had 
varying consensus motif sequences depending on which protein they were found (Table 
2.5), these classical NLS sites have been described by other authors (Lange et al., 2007).  The 
nuclear export signals were identified in the E1 protein and have been previously described 
(Bergvall et al., 2013a). The DNA recognition motif was found in the E2 protein of all the 
novel HPV types, but HPV214 has a slightly different motif from the GxxNxLKCxRxR(x)8 
(Graham, 2016), with an Leucine to Threonine modification and the functionality of this 
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motif can only be investigated by functional assays. We observed a typical transmembrane 
binding domain in the L2 of the novel HPV types G(x)3G(x)3G (Wang and Roden, 2013, 
Bronnimann et al., 2013). Figure 2.4 shows domains in the E6 protein, a comprehensive 
outline of multiple sequence alignments of the ten novel HPV types’ proteins and those of 
their closest known relatives is demonstrated in Supplementary Figures 2.16 to 2.21 in the 
appendix to chapter 2, also see Table 2.5 for a summary of the conserved domains.  
Figure 2.4  Alignment of the E6 proteins of the novel HPVs and closely related HPVs.  
The positions of the PDZ binding domain and Zinc finger binding domains in E6 are indicated 
by the black boxes.  
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Table 2.5 Presence and frequency of potential conserved domains in the novel HPV types. 
Genes/ 
 Domain Motif  HPV211 HPV212 HPV213 HPV214 HPV215 HPV216 HPV219 HPV220 HPV221 HPV222 
region 
E6 
GATA Type Zinc fingers CxxC(x)29CxxC 2 2 2 NA 2 2 2 2 2 2 
PDZ binding domain x(T/S)x(L/V) 1 - 1 NA 1 1 1 - - - 
E7 
E7 Conserved region 1                            1 1 1 1 1 1 1 1 1 1 
GATA Type Zinc fingers CxxC(x)29CxxC 1 1 1 1 1 1 1 1 1 1 
pRB binding domain LxCxE  - - - 1 - - - - - 1 
E1 
ATP binding site G(x)4GK(T/S) 1 1 1 1 1 1 1 1 1 - 
Bipartite nuclear localisation signal KRK and KRRL 1 1 1 1 1 1 1 1 1 1 
Nuclear export domain putative 
(L/I)(x)2-
3(L/I)xx(L/I/V)x(L/I/V) 
1 - 1 1 1 1 1  1  1  1  
E2 
Leucine zipper domain  Lx6Lx6Lx6L - - - - - - - - - - 
DNA recognition helix GxxNxLKCxRxR(x)8 1 1 1 1* 1 1 1 1 1 1 
Nuclear localisation domain RKRxR/KRRR/KRXR 1 1 1 1 1 1 1 1 1 1 
L1 Nuclear localisation like domain K(K/R)R(K/R) 1 1 1 1 1 1 1 1 1 1 
L2 
Nuclear localisation like domain (K/R)3R(K/R) 1 1 1 1 1 1 1 1 1 1 
Transmembrane binding domain G(x)3G(x)3G 1 1 1 1 1 1 1 1 1 1 
Furin cleavage site Rx(K/R)R 1 1 1 1 1 1 1 1 1 1 
Early polyadenylation site AAT(A)3 1 - 1 1 1 1  1  1  1 1  
LCR 
E2 binding sites  ACC(N)6GGT 3 3 1 3 3 2 1 2 2 2 
TATA binding box  TAT(A)3 1 1 1 1 1 1  1  1  1  1 
Late polyadenylation site AAT(A)3 1 1 1 1 1 1  1  1  1  1 
N represents any nucleotide, and x represents any amino acid. 
Long control region (LCR), 
Retinoblastoma binding protein (pRB)  
*The DNA recognition motif of HPV214 E2 has a L to T modification GxxNxTKCxRxR(x)8) 
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2.2.3 SEQUENCE SIMILARITY AND PHYLOGENY 
Pairwise comparison of all the novel types showed more than 60% identity to each other 
meaning they are members of the same genus but different species with the exception of 
HPV215 and HPV216 (72%) which belong to the same species, Gamma-9 (Bernard et al., 
2010). In terms of the most closely related known HPV types, HPV211 was most closely 
related to HPV168 with a pairwise identity of 72% based on the L1 nucleotide sequence, 
HPV212 to HPV144 with a pairwise identity of 82.9%, HPV213 to HPV153 with a pairwise 
identity of 71.8%, HPV214 to HPV103 with a pairwise identity of 75.3%, HPV215 to HPV129 
with a pairwise identity of 76.8% and HPV216 was to HPV129 with a pairwise identity of 
79.2% (Table 2.6 and Figure 2.5). HPV211 clustered in the Gamma-8, HPV212 in the Gamma-
17, HPV213 in the Gamma-13 and HPV214 in the Gamma-6 species, HPV215 and HPV216 
clustered with HPV129 of the Gamma-9 species as shown in the maximum likelihood tree 
(Figure 2.5). HPV219 is phylogenetically most closely related to HPV213 (87% identity in L1 
gene) of the Gamma-13 species, HPV220 to HPV212 (72%) of Gamma-17, HPV221 to 
HPV142 (80%) of Gamma-10, HPV222 to HPV162 (73%) of Gamma-19 (Table 2.6), as also 
shown in the maximum likelihood tree (Figure 2.5). The  HPV genotypes share <90% identity 
in the L1 gene (Bernard et al., 2010), all ten viruses are therefore novel genotypes.  
For all the putative ORFs, nucleotide and amino acid percentage pairwise identities to the 
closest recognised HPV types are shown in Table 2.6, and all were closely related to 
members of the Gamma-PVs genus. 
 69 | P a g e  
 
Table 2.6 Nucleotide (amino acid) percentage pairwise identity to closest HPV type.  
 
  HPV211 HPV212 HPV213 HPV214 HPV215 HPV216 HPV219 HPV220 HPV221 HPV222 
HPV type most 
closely related (% 
identity) 
HPV168 (72) HPV220 (72) HPV219 (87) HPV103 
(75.3) 
 
HPV 129  
(76.8) 
HPV129 
(79.2) 
HPV213 (87) HPV212 (72) HPV142 (80) HPV162  
(73) 
Gamma-species 8 17 13 6 9 9 13 17 10 19 
E6 66 (51) 87 (89) 72 (56) - 73 (69) 84 (83) 71(52) 73(62) 79(78) 72(66) 
E7 70 (55) 88 (87) 73 (61) 74 (69) 77 (74) 80 (76) 76(61) 80(44) 91(88) 73(68) 
E1 69 (61) 88 (92) 75 (71) 72 (65) 79 (77) 85 (88) 76(72) 73(69) 86(86) 75(70) 
E2 67 (55) 90 (90) 72 (56) 70 (62) 75 (70) 82 (76) 71(55) 74(67) 85(82) 71(60) 
E4 69 (44) 89 (81) 79 (40) 72 (63) 74 (60) 83 (75) 75(37) 75(62) 84(78) 74(60) 
L2 65 (53) 80 (85) 70 (52) 71 (62) 69 (65) 77 (75) 68(46) 68(61) 80(85) 68(64) 
L1 72 (71) 83 (92) 72 (68) 75 (75) 77 (80) 79 (87) 76(67) 69(77) 83(89) 71(71) 
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Figure 2.5 Maximum likelihood tree of the novel HPV types and related types.  
Generated from Muscle alignment (Edgar, 2004a) of L1 nucleotide sequences in PHYML 
(Guindon et al., 2010) with GTR substitution. Approximate likelihood ratio test branch 
support values are indicated on the branch lines. Blue indicates the novel HPVs, black, 
yellow, red, purple and green branches represent the Gamma-HPVs, Nu-HPVs, Alpha-HPVs, 
Beta-HPVs and Mu-HPVs, respectively.  
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2.2.4 INTRA-SAMPLE VARIATIONS 
All ten clones of HPV211, eight of HPV214, three of HPV216, ten of HPV219 and ten of 
HPV221 were identical and showed 100% pairwise identity. The ten clones of HPV213, and 
six of HPV215, and nine of HPV212, four of HPV220 and five clones of HPV222 were not 
100% identical (but at least >99.5% identical). It was noteworthy that not all the clones that 
were sequenced had useful sequences especially after quality checks and trimming, hence 
the reduced number of clones per novel type during the analysis stage. Analysis of 
mismatches between the nine genomic clones of HPV212 showed a total of 67 positions 
that varied along the 7208 bp genome (Figure 2.6). All the HPV212 clones were unique. 
Analysis of mismatches between the 10 genomic clones of HPV213 showed a total of 51 
mismatch positions that varied along the 7096 bp genome (Figure 2.5). HPV213 had 5 
unique clones. The six genomic clones of HPV215 showed a total of 50 mismatch positions 
along a 7186 bp genome (Figure 2.6). HPV215 had 3 identical and 3 different clones (Figure 
2.5). HPV220 had 4 different genomic clones that showed 17 mismatch positions along a 
7381 bp genome. The 5 different clones of HPV222 showed a total of 24 mismatch positions 
along the 7275 bp genome (Figure 2.7). 
Nucleotide changes that resulted in amino acid changes in the different ORFs are shown in 
Figure 2.8 and Figure 2.9. There were no non-synonymous changes in conserved functional 
domains except for two HPV213 clones that had a change from Cysteine to Phenylalanine at 
the last position of the E7 Zinc finger Binding Domain. In summary, percentage amino acid 
substitutions for HPV212 clones ranged from 0.98% in the L2 ORF to 2.67% in the E1 protein, 
for HPV213 clones from 0% in the E7 protein to 1.18% in the L1; HPV215 from 0.56% in the 
E4 to 1.79% in the L2, for HPV220 clones from 0.18% in L2 to 0.78% in L1 and lastly for 
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HPV222 clones amino acid substitution ranged from 0.5% in E1 to 0.78% in the L1 protein. 
Table 2.7 and Table 2.8 show that all the proteins of the novel HPV types had dN/dS ratios 
less than 1, which is indicative of negative selection pressure or purifying selection. 
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Figure 2.6 HPV212, HPV213 and HPV215 nucleotide mismatch positions. 
Positions of mismatches are based on the prototype Reference sequences (HPV212-1, HPV213-7 and HPV215-5) deposited in Genbank. 
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Figure 2.7 HPV220 and HPV222 nucleotide mismatch positions. 
Positions of mismatches are based on the prototype Reference sequences (HPV220-5 and HPV222-1) deposited in Genbank.
 
E7 
 
E1 
   
E2 
   
L2 
  
L1 
 
        
  
LCR 
Variants 470   1159 1577 2385   2561 2819 3202   3854 4763   5477 5673 5951 6290 6596   6868 6898 7042 
HPV220-5 C   A T A   A G A   T T   T A A T C   C T C 
HPV220-1 T   T . G   . . .   . C   C . . C .   T . T 
HPV220-2 .   . . .   . . .   . .   . . . . .   . . . 
HPV220-3 .   . C .   G A G   C .   . G G . G   . C . 
 E1  E2   L2   L1 LCR 
Variants 94
7 
104
9 
128
7 
166
6 
196
5 
201
4 
224
2 
  270
8 
310
8 
327
3 
353
1 
  364
6 
433
3 
472
9 
473
8 
476
4 
  548
2 
554
7 
599
3 
629
8 
644
2 
653
7 
655
2 
  67
38 
HPV222-1A A A T G . A G   A T A A   A A T G C   A A C G T . T   A 
HPV222-2C . . . . . G .   . . G G   . . A A T   G G T A . . .   . 
HPV222-3G G G . . A . .   . . G .   G . . . T   . . . A C . C   . 
HPV222-3E . . .C C . . A   G C G .   . G . . T   . . . A . A .   G 
HPV222-2A . . . . . . .   . . . .   . . . . .   . . . . . . .   . 
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Figure 2.8 Amino acid variations in the predicted proteins of the HPV212 clones (with clone 1 as reference), HPV213 clones (with identical 
clones 7 and 8 as reference clones) and HPV215 clones (with clone 5 as the reference). 
 76 | P a g e  
 
 
 
Figure 2. 9 Amino acid variations in the predicted proteins of the HPV220 clones (with lone 1 as reference), HPV222 clones (with identical 
clones 7 and 8 as reference clones).  
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In total, 67 nucleotide mismatches positions along a 7208 bp were observed for HPV212, 51 
mismatches positions for HPV213 along a 7096 bp and 50 mismatches for HPV215 along a 
7186 bp length. Showing that all the HPV212 clones were different and hence the one 
closest to the consensus in identity was chosen as the “type” sequence. HPV212-1 was 
selected and annotated as shown in Figure 2.10. HPV213 clones are different (however, 
clone 9 and 10 were identical, as were 1 and 4; 5 and 6;  2 and 3 as well as 7 and 8). Hence 
the one closest to the consensus in identity was chosen. HPV213-7/8 were selected and 
annotated as the representative sequence for Genbank purposes as shown in  Figure 2.10. 
HPV215 clones 2, 3 and 4 were similar and closer to the consensus, yet different from clones 
1, 5 and 6. HPV215-5 was however selected as the representative sequence for Genbank 
purpose as also shown in Figure 2.11. 
In total 17 nucleotide mismatches positions along a 7381 bp were observed for HPV220, 24 
mismatches positions for HPV222 along a 7275 bp. 
The nucleotide mismatch positions for HPV212, HPV213, HPV215, HPV220 and HPV222 
were also analysed using an online single nucleotide highlighter (Keele et al., 2008) originally 
designed for identification of HIV mutations. The results of this analysis are shown in Figures 
2.9 to 2.11. The mismatches do not pinpoint exact positions, but the Figures are intended to 
give a visual inspection of the amount of mismatched positions and how they are 
distributed along the sequences. These Figures used as visual representations, were also 
essential in visualizing the sequence closest to the consensus, which would then be chosen 
as the prototype reference sequence that was eventually send to the HPV International 
Reference Centre for nomenclature. HPV220 clones 5 and 2 were identical, yet different 
 78 | P a g e  
 
from clones 1 and 3. HPV220-5/2 were however selected and annotated as the 
representative sequences for submission to Genbank as shown in Figure 2.11. HPV222 
clones 1A and 2A were similar and closer, yet different from clones 3G, 2C and 3E. HPV222-
1A was however selected and annotated as  as the representative sequence for Genbank as 
shown in Figure 2.12. 
Despite all the varying mismatch positions in the different sequences/variants of each clone, 
all the clones of each type showed between 99.5% to 100% pairwise identity to each other 
(Figure 2.13 and Figure 2.14). This is less than 0.5% difference in the sequences of the 
various clones indicating that they were not variants nor sub-lineages according to strict 
HPV nomenclature rules (Burk et al., 2013).  
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Figure 2.10 HPV212 (labelled as CT03 isolates) Clones aligned against the CT03 consensus sequence, HPV213 (labelled as CT04 isolates) Clones aligned 
against the CT04 consensus sequence.  
Figure 2. 11  HPV215 (labelled as CT07 isolates) 
Clones aligned against the CT07 consensus 
sequence.  
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Figure 2.11 HPV215 (labelled as CT07 isolates) Clones 
aligned against the CT07 consensus sequence.  
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Figure 2.12 A) HPV220 Clones (labelled as 
CT08 isolates) aligned against the CT08-5 
as master sequence.  
B) HPV222 Clones (labelled as CT17 
isolates) aligned against the CT17-1A as 
master sequence. 
A 
B 
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Figure 2.13 Percentage pairwise identities of the different clones of HPV212, HPV213 and 
HPV215.  
Values of each pairwise identity of a given clone are connected by lines (colored differently for 
visual aid) and comparison to self is indicated by 100% pairwise identity point.  
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Figure 2.14 Percentage pairwise identities of the different clones of HPV220 and HPV222. 
Values of each pairwise identity of a given clone are connected by lines (colored differently for 
visual aid) and comparison to self is indicated by 100% pairwise identity point.  
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Table 2.7 Comparison of nucleotide and amino acid sequence variability and synonymous to 
non-synonymous changes within HPV212, HPV213 and HPV215 genes. 
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Table 2.8 Comparison of nucleotide and amino acid sequence variability and synonymous to 
non-synonymous changes within HPV220 and HPV222 genes. 
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Figure 2. 15 is a summary of the dN/dS ratios of all the ORFs of the five novel HPV types that 
showed variation among clones. A ratio of one indicates neutral evolution with values below 
one suggesting purifying selection (negative selection) and values more than one Darwinian 
selection (positive selection). It is apparent that all the ORFs show values below one. The E1, E2 
and L1 across all the novel types showed some values at least above 0.2 although still below 
one.  
 
Figure 2.15 dN/dS ratios of each ORF of HPV212, HPV213, HPV215, HPV220 and HPV222. 
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2.3 DISCUSSION 
This chapter describes the identification and characterisation of ten novel Gamma-HPVs. The 
amplification of whole genomes of these viruses from short L1 fragments using back to back 
primers in a long-range PCR using a touch down approach. Further described here is the cloning 
of the full genomes of the novel viruses and the application of NGS to construct by de novo 
assembly the genome sequences of these viruses. The application of several bioinformatics 
tools to characterise the viral sequences in terms of: genome organisation, conserved domains, 
phylogeny, genome sequence variation from other known HPVs and evolutionary selection 
pressures is also reported here. The curated sequences were then sent to the International 
Reference Centre in Karolinska, Sweden for verification and numbering. The ten novel viruses 
were confirmed as novel HPV types and assigned numbers HPV211 to HPV216 and HPV219 to 
HPV222 (http://www.nordicehealth.se/hpvcenter/reference_clones/). We deposited the 
sequences in Genbank under accession numbers: HPV211 MF509816, HPV212 MF509817, 
HPV213 MF509818, HPV214 MF509819, HPV215 MF509820, HPV216 MF509821, HPV219 
MH172376, HPV220 MH172377, HPV221 MH172378 and HPV222 MH172379. 
Most Gamma-PVs have been isolated from cutaneous lesions, but most of the novel types 
described in this thesis are related to Gamma-PVs that were also isolated from mucosal or 
anogenital tissue.  HPV211 clustered with the Gamma-8 species alongside five other members. 
HPV212 became the second member of Gamma-17 species after the sole member HPV144 
which was isolated from an oral rinse (Bottalico et al., 2011a). HPV213 became the third 
member of the Gamma-13 species after HPV153 which was isolated from a condyloma 
(Sturegard et al., 2013) and HPV128 which was isolated from a skin wart (Kohler et al., 2011) . 
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HPV215 and HPV216 became third and fourth  members of the Gamma-9 species after HPV129 
which was isolated from a skin wart  and HPV116 which was isolated from a rectal swab 
(McLaughlin-Drubin and Munger, 2009b). HPV214 became the fourth member of Gamma-6 
species after HPV101 and  HPV103 which had been isolated from cervico-vaginal cells (Chen et 
al., 2007b) and HPV108 was isolated from a cervical lesion (Nobre et al., 2009b). HPV214 was 
also identified as HPVX by metagenomics sequencing of cervical DNA (Ameur et al., 2014b).  
Future studies should examine whether Gamma-6 viruses can be identified in other mucosal 
and cutaneous sites. In addition to the lack of E6, it is apparent from the phylogenetic tree 
(Figure 2.4) that the four members of the Gamma-6 species, including the novel HPV214 
described in this study, have a considerable phylogenetic distance from other Gamma-HPV 
types (see chapter 3 with predicted divergence times). 
The E5 protein is only present in Alpha-HPVs and absent in Beta-, Gamma-, Mu- and Nu-
papillomaviruses (Venuti et al., 2011). The functions of this 90 aa protein in high risk HPVs 
range from the binding of platelet derived growth factor (PDGF) and activating it, induction of 
cell transformation and MHC class 1 antigen presentation inhibition (thereby evading immune 
response) (Stanley et al., 2007). However, Gamma-HPVs in the absence of E5 proteins are still 
able to evade the immune system by interfering with IFNγ anti-viral pathway (Woodby et al., 
2016).  There are thus always compensatory evolutionary mechanisms developed over time to 
achieve the same biological end. 
The Gamma-6 species lack the E6 ORF and so do HPV214 (Nobre et al., 2009b). The E6 protein is 
essential in binding of p53 tumour suppressor protein and cell cycle dysregulation (Wallace and 
Galloway, 2015). It appears however that this lost function in HPV214 may be compensated for 
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by its E7 protein as it has a LxCxE motif for pRB binding, which is lacked by the other novel types 
(Table 2.4). It has been shown elsewhere that HPV108, another member of the Gamma-6 
species can induce dysplasia  in organotypic keratinocytes without having the E6 protein (Nobre 
et al., 2009a), alluding to the fact that once the E6 binding function is not present there are 
compensatory mechanisms developed through evolution for the viruses to adapt to the host. It 
was recently shown that Gamma-6 HPVs acquired a 37 aa protein named E10, the E10 protein 
is upstream of the E7 start codon (Van Doorslaer and McBride, 2016, Van Doorslaer et al., 
2017a) (Figure 2.2). In this study, E10 was identified in HPV214. However, the acquisition of E10 
does not likely compensate for all E6 functions. 
Zinc fingers are finger-like zinc binding domains in protein sequences. These are essential in 
protein to protein interactions and binding to DNA (Wayengera, 2012). The E6 and E7 proteins 
of the novel HPVs have Zinc finger binding domains. In HPV16, the zinc domains facilitate E6 
binding to a number of cellular proteins including p53 (Wallace and Galloway, 2015). In high risk 
HPV types, the binding of p53 by E6 protein, in combination with the E7 protein binding of pRB, 
constitutes the hallmark of HPV carcinogenesis (Munger et al., 2004). The E7 protein of most 
oncogenic HPVs contain a pRB binding domain represented as LxCxE (Doorbar et al., 2015), and 
of the novel types only HPV214 and HPV222 contained this domain.  
We found nuclear localisation like sequences (NLS) in E1, E2, L1 and L2 proteins of all the novel 
HPV types. In the L1 and L2 proteins they were NLS-like signals with slight modifications from 
the KRK and KRRL signatures, as reported in HPV16 (Zhou et al., 1991) and HPV199 (Ostrbenk et 
al., 2015). NLS signal motifs were identified in the C-terminus of the L1 and L2 proteins of the 
novel Gamma-HPVs with the motif (K/R)R(K/R), these have also been described elsewhere 
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(Zhou et al., 1991, Nelson et al., 2000).  E1 proteins play a primary role in viral DNA replication 
and hence are found in the nucleus of the host cell. To facilitate this function, E1 proteins have 
amino acid sequences that are necessary for directing this nuclear localisation (Ostrbenk et al., 
2015). E1 proteins have a bipartite NLS composed of two clusters separated by about 27-30 aa 
(KRK and KRRL) among the novel types, they were separated by 28aa. Another conserved NLS 
motif RKRxR/KRRR/KRXR, previously described in Alpha-HPVs (Zou et al., 2000) and also 
promotes nuclear localization was also found in the E2 proteins of the Gamma-HPVs.  
Other domains identified include the PDZ binding domain in the N-terminal region of E6 (Bolatti 
et al., 2016), ATP binding site of E1, the DNA recognition helix of E2 and the furin cleavage site 
of L2. All these domains play a role in the HPV life cycle, the details of the mechanisms of their 
action are beyond the scope of this chapter. However, the transmembrane domain at the N-
terminal of the L2 minor capsid protein has recently been described in HPV16 as essential for 
the translocation of viral DNA across phospholipid bilayer membranes (Bronnimann et al., 2013, 
Wang and Roden, 2013). The domain consists of G(x)3G motifs and similar glycine zippers 
G(x)3G(x)3G motifs that together work in unison to facilitate packing of DNA helices to pass lipid 
bilayers. This domain was also identified in all the L2 proteins of the novel types but its 
functionality in Gamma-HPVs has not been explored. 
LCR palindromic E2 binding sites (ACC-N6-GGT) Li et al. (2009) were present in all the novel HPV 
types, these have also been described elsewhere (Newhouse and Silverstein, 2001). The origin 
of replication of PVs lies in the LCR and contains more than one E2 binding site (Sverdrup and 
Khan, 1995). The E2 protein acts as an activator as well as a repressor of viral transcription and 
initiation of replication, partitioning of genome and binds to two forms of palindromic sites:  
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ACC-(N)4-CGGT and (ACC-N6-GGT). The former site binds with higher affinity compared to the 
latter (Bedrosian and Bastia, 1990). The novel HPVs described in this study had the latter form 
of the palindromic binding sites which bind weakly, but this may not apply to the E2 from the 
novel types. 
Polyadenylation sites are adenine rich and facilitate viral mRNA splicing. The early sites are 
positioned at the 5’ end of the L2 protein, while the late polyadenylation sites are usually 
downstream of the L1 protein within the LCR (Chen et al., 2007a, Chen et al., 2007b). We 
identified early polyadenylation sites (-AATAAA-) at the N-terminal (5’) end of the L2 protein of 
all the novel HPV types. The late polyadenylation sites were located in the URR region but at 
differing positions in each novel type. 
In this study, we showed that HPV212, HPV213, HPV215, HPV220 and HPV222 novel types each 
had full genome clones with at least 99.5% pairwise identity to each other (Figure 2.9 and 
Figure 2.10). It has been suggested that differences in a single genetic region cannot be used to 
define a variant, but rather that the complete genome be used for variant classification instead 
of just the L1 ORF (Chen et al., 2015). A common nomenclature for HPV variants and sub-
lineages using complete genomes has been implemented (Burk et al., 2013). The complete 
genomes of each of HPV212, HPV213, HPV215, HPV220 and HPV222 clones displayed <0.5% 
pairwise difference in nucleotide sequences. By strict definition a sub-lineage is an isolate of the 
same HPV type that differs from the other by a minimal of 0.5% and maximal of 1% difference 
(Calleja-Macias et al., 2005, Bernard et al., 2006, Burk et al., 2013) and hence the clones do not 
fit the definition of sub-lineages according to Burk and co-workers (Burk et al., 2013). 
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The intra-host genetic diversity of the novel Gamma-HPVs was examined here by Illumina 
sequencing of multiple whole genome clones of each type amplified from individual clinical 
specimens. This is the first study of intra-host variation of Gamma-HPVs. While there was no 
variation in the genomes of HPV211, HPV214, HPV216, HPV219 and HPV221, we identified 67, 
51, 50, 17 and 24 variable nucleotide sites in the genomes of HPV212, HPV213, HPV215, 
HPV220 and HPV222 respectively. This diversity was greater than expected after having run two 
PCRs for each novel type to rule out polymerase-based artefacts. PVs have long been thought 
to have a low rate of mutation and to co-evolve with their hosts (Bravo and Felez-Sanchez, 
2015, Chen et al., 2009, Dube Mandishora et al., 2018) due to the fact that they hijack the host 
cellular DNA replication machinery for replication which includes high fidelity polymerases with 
proofreading activity (with an error rate of about 4.3 x 10-5 (Korona et al., 2011)) and post-
replication repair. However, similar to our findings, several recent NGS-based studies report 
high intra-host variability in Alpha-HPVs in clinical specimens, the studies using Ion Torrent 
sequencing of long PCR amplicons of the HPV16 genome identified between 3 to 175 variable 
nucleotide sites per genome in samples (Dube Mandishora et al., 2018, de Oliveira et al., 2015, 
Hirose et al., 2018). Hirose and co-workers (Hirose et al., 2018) identified an average of 7 
nucleotide variations (range 0 to 85) per sample in the genomes of HPV16, HPV52 and HPV58. 
Dube Mandishora and co-workers (Dube Mandishora et al., 2018) identified hundreds of 
variant sites in the PGMY region of the L1 gene of HPV16, HPV18 and HPV52 using Illumina 
sequencing. Several explanations have been proposed for the high variability observed, 
including the generation of variants during infection due to the activation of host polymerases 
with lower fidelity (Dube Mandishora et al., 2018) as well as the recruitment of members of the 
apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like (APOBEC) family of 
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mutagenic enzymes (Hirose et al., 2018, Mirabello et al., 2017, Vartanian et al., 2008) resulting 
in mutations rates higher than the human autosomal mutation rate.  
The dN/dS ratios were calculated, with a ratio of one indicating neutral selection, >1 diversifying 
positive selection and <1 negative or purifying selection (Chen et al., 2009). The dN/dS ratios for 
all ORFs of HPV212, HPV213, HPV215, HPV220 and HPV222 were less than 1 indicating purifying 
selection (Table 2.6 and Table 2.7). This is in agreement with previous findings that the ORFs of 
HPV16 and other Alpha-HPVs are under strong purifying selection (DeFilippis et al., 2002, 
Carvajal-Rodriguez, 2008, Chen et al., 2005). Purifying selection is likely the result of the 
requirement for maintaining functional viral proteins for the successful completion of the virus 
life cycle. Gamma-HPVs are usually commensals with non-pathogenic and non-oncogenic 
potential and hence the absence for the need to be constantly under diversifying positive 
selection as a result of the need for immune escape. The combination of the lack of diversifying 
positive selection coupled with high intra-host variation in 5 of the novel HPV types maybe 
indicative of the fact that the variation observed is not an evolutionary event but random 
changes during replication of viral genome. This is supported by the fact that if it were an 
evolutionary event, we would have also identified more variations occurring among conserved 
functional domains. There were no non-synonymous changes in conserved functional domains 
except for a Cysteine to Phenylalanine substitution at the last position of the E7 Zinc finger 
binding domain found in two HPV213 clones. Whether this amino acid change is deleterious to 
the functioning of E7 was not explored.  
Strikingly, we also observed that all of the novel HPV types had dN/dS values of less than 1 
(indicative of purifying selection) in both the E6 and E7 protein (Figure 2.11). In Alpha-HPVs, the 
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E6 and E7 play a major role in oncogenesis as they have the retinoblastoma binding domain and 
Zinc finger binding domains essential in binding the p53 tumour suppressor protein. The lack of 
diversifying selection and presence of selection in the E7 of most Gamma-HPVs are probably 
indicative of the non-oncogenic potential of these viruses, as they do not exhibit any selection 
pressure. 
2.4 CONCLUSIONS 
The characterisation and classification of HPV211, HPV212, HPV213, HPV214, HPV215, HPV216, 
HPV219, HPV220, HPV221 and HPV222 add these novel types to the repertoire of the ever 
expanding Gamma-HPV genus. We make the fourth announcement of an HPV lacking the E6 
ORF. It is apparent from the phylogenetic tree (Figure 2.4) based on L1 nucleotide sequences 
that the four members of the Gamma-6 species, besides the unusual genome lacking the  E6 
ORF, also have a considerable phylogenetic distance from other HPV types. Further 
investigations into the Gamma-6 species, tissue tropism and potential disease association of the 
other novel HPVs described here is warranted, in order to empirically evaluate their clinical 
significance. We recommend further studies into intra-host viral diversity. 
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Chapter 3: Evolutionary Dynamics of Ten Novel Gamma-PVs: Insights from 
Phylogenetic Incongruence, Recombination and Phylodynamic Analyses 
3.0 INTRODUCTION    
The discovery of numerous new PVs using next generation sequencing methods has begun to 
shed further light on the evolutionary history of this virus family. However, unravelling the 
evolutionary history of these viruses is potentially complicated by both inter-gene phylogenetic 
incongruence and recombination (Van Doorslaer, 2013). It has been observed that the 
nucleotide and encoded amino acid sequences of the E and L genes have evolved slightly 
differently in terms of evolutionary rates and selection pressures (Harari et al., 2014, García-
Vallvé et al., 2005), a factor that could contribute to phylogenetic incongruence between the E 
and L gene trees. As a consequence of this, no single gene tree will accurately and adequately 
represent the evolutionary history of complete PV genomes (Van Doorslaer, 2013). 
Recombination events between different PVs may provide an additional explanation for gene-
to-gene phylogenetic incongruence. 
The genetic diversity and plurality of PVs along with the high frequencies of  observed HPV co-
infections make it reasonable to hypothesize recombination (Angulo and Carvajal-Rodriguez, 
2007). However, technical difficulties associated with the inaccurate alignment of highly diverse 
PV gene sequences has slowed the study of recombination among PVs (Posada and Crandall, 
2001). One of the most cited methods for recombination detection is the RDP program, which 
is a combination of rigorous alignment quality testing and powerful recombination detection 
methods (Varsani et al., 2006).  During recombination detection, RDP4 rigorously tests the 
quality of sequence alignments to guard against the detection of false-positive recombination 
signals that arise due to sequence misalignment (Varsani et al., 2006).  
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We report in this chapter phylogenetic incongruences, recombination analysis and time 
evolution of the ten novel Gamma-PV types from humans, HPV211-HPV216 and HPV219-
HPV222 (Murahwa et al., 2018), which we use along with all currently known members of the 
Gamma-PV genus and other PVs to describe the evolution of PVs. 
3.1 METHODS 
3.1.1 SOURCE OF SEQUENCE DATA 
Sequences were downloaded from PaVE database (https://pave.niaid.nih.gov accessed on 
27/01/2018). The sequences for HPV211-HPV216 and HPV219-HPV222 were obtained from our 
group (Murahwa et al., 2018). PVs are classified by the International Committee on Taxonomy 
of Viruses (Van Doorslaer et al.) into distinct species but the nomenclature of types can be done 
by specific working groups. Some of the viruses used in this study are pending classification by 
the ICTV, but were provisionally grouped into specific genera and types by the HPV Reference 
Centre in Sweden (http://www.nordicehealth.se/hpvcenter/reference_clones/).  
3.1.2 PHYLOGENETIC TREE CONSTRUCTION 
Construction of phylogenetic trees for incongruence tests: The sequences of the ten novel HPV 
types and the ten publicly available HPV sequences that were most closely related to each of 
these were used to construct phylogenetic trees. Phylogenetic trees were constructed based on 
MUSCLE (Edgar, 2004a) alignments of the nucleotide sequences of each ORF obtained from the 
PAVE database (Van Doorslaer et al., 2013a). Maximum likelihood trees were generated with 
PhyML 3.0 (Guindon et al., 2010) using the general time reversible nucleotide substitution 
model with discrete gamma rate heterogeneity among sites and invariable sites (GTR+G+I), as 
determined to be the best fitting nucleotide substitution model by jmodeltest (Darriba et al., 
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2012). The approximate likelihood ratio test (aLRT) was used to estimate branch support 
(Anisimova and Gascuel, 2006). The trees were visualised in iTOL  
(http://itol.embl.de/upload.cgi) (Letunic and Bork, 2016). 
3.1.3 PHYLOGENETIC INCONGRUENCE TESTS 
We applied two different phylogenetic incongruence tests the Ktreedist test as a preliminary 
test and the Shimodaira-Hasegawa test. 
The Ktreedist test: To determine the joint differences in topology and branch lengths between 
phylogenetic trees constructed from different HPV genes (E1, E2, E4, E7, L1, and L2),  we 
utilised Ktreedist v1.0 (Soria-Carrasco et al., 2007).  In brief, the Ktreedist program first scales a 
comparison tree to match the global divergence of a reference tree and then measures 
minimum branch length distances (BLD) between the trees: known as the tree K-score. K-scores 
close to 0 indicate that the phylogenetic trees being compared are very similar, i.e. they have 
similar branching orders and relative branch lengths, irrespective of their global evolutionary 
rates (Soria-Carrasco et al., 2007). High K-scores imply that trees are incongruent (Soria-
Carrasco et al., 2007). 
The Shimodaira-Hasegawa test (Shimodaira and Hasegawa, 1999) using W-IQ-TREE 
(Trifinopoulos et al., 2016): We used clustal alignments (Sievers et al., 2011, Li et al., 2015, 
McWilliam et al., 2013) of E1, E2, E4, E7, L1 and L2 HPV genes from 80 Gamma-HPVs (including 
the ten novel types) to compute the log-likelihoods of phylogenetic trees in W-IQ-TREE, which is 
a fast online phylogenetic tool for maximum likelihood analysis (http://iqtree.cibiv.univie.ac.at) 
(Trifinopoulos et al., 2016). The tool test tree topology estimates model parameters such as 
substitution rates and optimizes tree branch lengths to lessen computational usage. We used 
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default settings of the W-IQ-Tree, including best fit model (Kalyaanamoorthy et al., 2017) and 
ultra-fast bootstrap analysis (1000 alignments) (Minh et al., 2013) to run tree topology analysis 
including the Kishino-Hasegawa (KH) test (Kishino and Hasegawa, 1989), Shimodaira-Hasegawa 
(SH) test (Shimodaira and Hasegawa, 1999) and approximately unbiased (AU) test (Shimodaira, 
2002) to test if there is a difference in evolutionary patterns amongst the different HPV genes. 
The results of the Shimodaira-Hasegawa test using W-IQ-Tree are shown in the appendix to this 
chapter as supporting evidence. 
3.1.4 RECOMBINATION ANALYSIS 
Seventy complete Gamma-PV genomes that are representative of all currently known Gamma-
PVs obtained from the PAVE database, were combined into a dataset of 80 sequences with the 
ten novel HPV types recently discovered and genomically characterised by our group (Murahwa 
et al., 2018). All genomes were linearized at the first nucleotide position of their E6 genes 
except for Gamma-6 species viruses that lack E6 for which the start was shifted to the first 
nucleotide of their E7 genes. We then constructed an alignment containing the 80 Gamma-PVs 
using MUSCLE. This alignment was analysed using RDP v4.95 (Martin and Rybicki, 2000) with 
default settings, which implements analysis of recombination using several methods: RDP 
(Martin and Rybicki, 2000), BOOTSCAN (Martin et al., 2005a), CHIMAERA (Martin et al., 2005b), 
GENECONV (Padidam et al., 1999), MAXIMUM X2 (Smith, 1992) and SISCAN (Gibbs et al., 2000). 
3.1.5 CONSTRUCTION OF A TIME-SCALED HPV PHYLOGENY 
We sought to infer the probable divergence times of our newly characterised HPV types from 
currently known HPVs. The complete L1 nucleotide sequences from 214 PV sequences were 
selected for analysis (Table 3.1). Two avian PVs: FcPV (Fringilla coelebs, the common chaffinch), 
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PePV (Psittacus erithacus, the grey parrot) and one turtle PV: CcPV1 (Caretta caretta, the 
loggerhead turtle) were also included in the analysis as outgroups. We performed a Bayesian 
evolutionary molecular clock analysis using BEAST v1.8.4 (Drummond et al., 2012). With a 
GTR+I+G nucleotide substitution model and an uncorrelated lognormal relaxed clock model. A 
fixed mean substitution rate for HPVs was applied based on estimated evolutionary rates 
inferred from a study that investigated the times to the MRCA based of Feline papillomaviruses 
(1.95 x 10-8  nucleotide substitutions per site per year) (Rector et al., 2007). The Markov Chain 
Monte Carlo (MCMC) analysis was run for 100,000 million generations with sampling every 
10,000 generations. The final MCMC sampling chains were visually assessed for convergence 
and good mixing using Tracer v1.7.1 (Rambaut et al., 2018). A Maximum Clade Credibility (MCC) 
tree was generated after discarding the first 1000 trees that were obtained prior to the burn-in 
period of the chains.  
Table 3.1 Summary of Analysis done and sequence dataset used. 
Type of analysis Sequence data set used 
Phylogenetic tree construction 80 whole genomes of currently known Gamma-HPVs  
K-treedist test (run as a preliminary 
test for incongruence ) 
10 novel Gamma-HPV types and 10 closely related Gamma-HPV types (also used for 
construction of preliminary gene phylogenetic trees in Figure 3.2) 
Shimodaira-Hasegawa test  80 whole genomes of currently known Gamma-HPVs 
Recombination analysis 80 whole genomes of currently known Gamma-HPVs 
Time scaled HPV phylogeny 
 
214 L1 nucleotide sequences of mostly HPV sequences, two avian PVs and one turtle 
PV. 
 
 
 100 | P a g e  
 
3.2 RESULTS 
3.2.1 PHYLOGENETIC INCONGRUENCE AMONG NOVEL GAMMA-PVS GENE TREES 
The Ktreedist yielded K-scores >0.45 which are indicative of substantial topological and branch-
length differences between many different pairs of trees. This was especially true for the early 
and late gene comparisons (Figure 3.1). The highest degree of incongruence was between L1 
and E7 (a K-score = 0.585; Figure 3.2). A high K-score (0.5) was also observed for the E7 vs E2 
gene comparisons.  Conversely, the L1 and L2 gene comparisons yielded the lowest K-scores 
(0.33). K score values are not symmetrical i.e. L1:L2 K score value differed from L2:L1 K score 
value. This preliminary result done for the 10 novel types and 10 of the closest known HPVs 
prompted further investigation of incongruence trees among all the currently known 80 
Gamma-HPVs. 
To determine if the phylogenetic trees for different Gamma-PV genes were congruent we then 
used a more conclusive test, the SH test (Shimodaira and Hasegawa, 1999). The null hypothesis 
of the SH test states that the difference between trees (branch length, topology or likelihoods) 
is zero. The observed differences were significantly greater than zero and rejected the null 
hypothesis for most of the gene versus gene comparisons, but particularly for the E gene versus 
L gene comparisons. Table 3.2 shows the results of the SH test using W-IQ-Tree, indicating that 
there is substantial phylogenetic incongruence between the late and early genes of Gamma-PVs 
as shown by the p-values (indicated in light blue in Table 3.2). The observed differences (deltaL 
values) were significantly greater than zero as shown by the p-values and allows us to reject the 
null hypothesis and declare that the trees are significantly different i.e. incongruent (p< 0.05). 
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The W-IQ-Tree results output are displayed in the appendix to this chapter (Supplementary 
Figures 3.6).  
Figure 3. 1 Minimum branch length distance (K tree score) between phylogenetic trees 
constructed using different HPV genes. 
 K-score values of closer to zero indicate that the phylogenetic trees are very similar, i.e. have 
similar topology and relative branch lengths, irrespective of their global evolutionary rates [33]. 
A high K-score value is an indication of incongruence regardless of global evolutionary rates.  
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Figure 3. 2 A representative phylogenetic incongruence between early and late genes among 
the 10 novel types and their closest known Gamma-PVs. 
Phylogenetic trees were inferred based on the L1 (left tree) and E7 (right tree) using MUSCLE 
alignment of the nucleotide sequences. Maximum likelihood trees were generated in PHYML 
with GTR substitution model with 1000 bootstrap replicates used for branch support estimation 
and viewed and edited in iTOL. Only the novel types were included in this analysis for 
readability. The dotted lines were added for ease of interpretation.  
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 E1 as reference tree  
Tree  deltaL  bp-RELL   p-KH p-SH   p-WKH  p-WSH     c-ELW  p-AU 
E1  0  1  1  1  1  1  1  0.999 
E2  182.16  0  0  0.008  0  0  7.3e-33  0.000747 
E4  639.14  0  0  0  0  0  3.8e-203  0.000845 
E7  1048.70  0  0  0  0  0  0  1.8e-58 
L1  381.21  0  0  0  0  0  3.8e-104  4.2e-05 
L2  219.47  0  0  0.002  0  0  1.2e-40  2.4e-09 
 E2 as reference tree  
Tree  deltaL  bp-RELL   p-KH p-SH   p-WKH  p-WSH     c-ELW  p-AU 
E1  137.43  0  0  0.023  0  0  1.3e-27  8.3e-05 
E2  0  1  1  1  1  1  1  1 
E4  288.35  0  0  0  0  0  1.3e-75  2.8e-07 
E7  904.92  0  0  0  0  0  3.4e-299  6.7e-97 
L1  273.21  0  0  0  0  0  5.9e-70  5.7e-44 
L2  224.96  0  0  0  0  0  1.8e-60  5.1e-07 
 E4 as reference tree  
Tree  deltaL  bp-RELL   p-KH p-SH   p-WKH  p-WSH     c-ELW  p-AU 
E1  79.74  0  0  0.012  0  0.004  0.000433  0.0217 
E2  64.99  0.02  0.003  0.02  0.003  0.016  0.00211  0.104 
E4  0  0.998  0.997  1  0.997  1  0.997  0.992 
E7  311.86  0  0  0  0  0  8.7e-85  5.8e-114 
L1  130.15  0  0  0  0  0  1.2e-23  6.4e-35 
L2  84.83  0  0  0.004  0  0  1.1e-10  0.00483 
 E7 as reference tree  
Tree  deltaL  bp-RELL   p-KH p-SH   p-WKH  p-WSH     c-ELW  p-AU 
E1  59374  0.004  0.016  0.017  0.016  0.064  0.00429  0.0117 
E2  71.02  0.001  0.007  0.007  0.007  0.031  0.000919  0.00182 
E4  138.43  0 0  0  0  0  1.78e-20  0.014 
E7  0  0.946  0.952  1  0.952  0.991  0.944  0.945 
L1  39.42  0.0041  0.048  0.119  0.048  0.189  0.043  0.118 
L2  59.86  0.008  0.022  0.025  0.022  0.063  0.00759  0.0321 
 L1 as reference tree  
Tree  deltaL  bp-RELL   p-KH p-SH   p-WKH  p-WSH     c-ELW  p-AU 
E1  188.69  0  0  0  0  0  1.3e-25  7.6e-05 
E2  218.51  0  0  0  0  0  4.1e-40  6.6e-48 
E4  473.21  0  0  0  0  0  1.6e-133  0.000267 
E7  899.66  0  0  0  0  0  3.5e-301  5.98e-65 
L1  0  1  1  1  1  1  1  1 
L2  149.83  0  0  0.005  0  0  9.9e-301  1.23e-10 
 L2 as reference tree 
Tree  deltaL  bp-RELL   p-KH p-SH   p-WKH  p-WSH     c-ELW  p-AU 
E1  226.34  0  0  0  0  0  2.4e-51  1.3e-52 
E2  220.29  0  0  0  0  0  1.8e-50  8.4e-12 
E4  478.78  0  0  0  0  0  1.5e-149  4.2e-06 
E7  1087.1  0  0  0  0  0  0  0.00124 
L1  229.72  0  0  0  0  0  1.3e-42  2.01e-13 
L2 0 1 1 1 1 1 1 1 
Table 3.2 Shimodaira-Hasegawa test for incongruence. 
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3.2.2 RECOMBINATION ANALYSIS 
The Gamma-PV whole genome alignments contained a total of only three plausible 
recombination events, namely event 1, 2 and 3. These events were all detectable by two or 
more different recombination detection methods with a p-value cut-off <0.05. However, event 
1 and event 2 had no phylogenetic support and were therefore disregarded. Event 3 suggested 
that HPV4 and its near relatives all share evidence of the same ancestral recombination event 
(Figure 3.3 and Table 3.3). Only one of our newly discovered novel HPV types, HPV221, is a 
potential recombinant. The remainder of the potential recombination signals from event 3 are 
shown in Table 3.3.  
Table 3.3 Inter-species recombination event 3 in whole genome Gamma-PVs. 
Estimated Break point positions 
Recombinant 
(Gamma-
species) 
           Parent sequence Evidence 
Intra-species or 
inter species 
recombination 
In Alignment  
In Genbank 
sequence 
Minor 
(Gamma-
species) 
Major (Gamma-
species) 
(method 
with P 
value < 
0.05) 
  
4446 8018 3631 6426 ^HPV4 (γ-1) HPV130 (γ-10) 
Unknown 
(HPV162)(γ-19) 
 M,C,S,3S Inter-species 
        HPV163[T]         
        HPV173[T]         
        HPV205[T]         
        HPV158[T]         
        HPV95[T]         
        HPV65[T]         
 
deltaL:  logL difference from the maximal logl in the set. 
bp-RELL:  bootstrap proportion using RELL method (Kishino et al., 1990). 
p-KH:  p-value of one sided (Kishino and Hasegawa, 1989). 
p-SH: p-value of Shimodaira-Hasegawa test (Shimodaira and Hasegawa, 1999). 
p-WKH: p-value of weighted KH test. 
p-WSH: p-value of weighted SH test. 
c-ELW: Expected Likelihood Weight (Strimmer and Rambaut, 2002). 
p-AU: p-value of approximately unbiased (AU) test (Shimodaira, 2002). 
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N.B. Only event 3 is shown in Table 3.3, all the potential recombinant Gamma-PVs for this event 
are shown in the recombinant column and the proposed major and minor parents. 
Abbreviations: M=MAXIMUM X2, S= SISCAN, C=CHIMAERA, 3S=3SEQ 
^ = The recombinant sequence may have been misidentified (one of the identified parents 
might be the recombinant.  
Minor Parent = Parent contributing the smaller fraction of sequence.  
Major Parent = Parent contributing the larger fraction of sequence.  
Unknown = only one parent and a recombinant need be in the alignment for a recombination 
event to be detectable the sequence listed as unknown was used to infer the existence of a 
missing parental sequence.  
[T] Sequences with trace evidence of the same recombinant event. 
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Figure 3. 3 Fast NJ tree from A) major parent (1-4445 and 8019-9792) and from B) minor 
parent (4446-8018). 
Red-potential recombinant, Orange-sequence with trace evidence of the same recombination event, Blue-potential minor 
parent, Green-sequence used to infer unknown parent 
 
Phylogenetic evidence of an ancient recombination event amongst Gamma-PVs. These 
unrooted neighbour joining trees (1000 bootstrap replicates, Jukes Cantor distances) were 
constructed in RDP v4.95 exported as Newick format and viewed in iTOL. Virus recombination 
methods indicate with a high degree of significance that the sequences in brown/orange are 
recombinant descendants of sequences in blue and green. 
 
 A 
B 
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3.2.3 THE TIME-SCALE OF GAMMA-PV EVOLUTION  
A fixed mean substitution rate for HPVs was applied based on estimated evolutionary rates 
inferred from that of Feline PVs (1.95 x 10-8 nucleotide substitutions per site per year) (Rector et 
al., 2007). The divergence times of the MRCA of HPV was predicted to have occurred 53.9 MYA 
(95% HPD 49.7-58.5), before splitting into the five main potential ancestors (Alpha, Beta, Mu, 
Nu and Gamma genera). The MRCA of the present day Gamma-PVs was predicted to have 
occurred approximately 49.8MYA (95% HPD 45.3-67.5). The novel HPV212 was predicted to 
have diverged from its closest relative, HPV144, about 7.6 MYA (95% HPD 5.2-10.4), the 
remaining nine novel Gamma-PVs divergence times from the MRCA are shown in Table 3.4. The 
predictions lie between 7.6 to 19.9 MYA. 
Table 3.4 Mean divergence time of 10 novel HPVs from other gamma species or closest 
relative. 
Since it has been reported that between 10 and 20 MYA, several hominoid precursors lived in 
Africa, Europe and Asia (Andrews, 1992), the timing and spatiotemporal patterning of 
Neanderthal human precursors’ disappearance has only been radiocarbon dated to a limit of 
HPV types Gamma-Species Posterior Mean Divergence Time (95% HPD) from MRCA 
HPV211 8 1 19.9 (16.8 - 23.1) MYA from all other Gamma-8 species HPV types 
HPV212 17 1 7.6 (5.2 - 10.4) MYA from its closest relative HPV144 
HPV213 13 1 5.4 (4.0-7.1)   MYA from its closest relative HPV219 
HPV214 6 1 17 (12.8-20.7)   MYA from closest relatives HPV108 and HPV103 
HPV215 9 1 11.3 (9.2-13.7)   MYA from closest relative HPV216 and HPV129 
HPV216 9 1 8.3 (6.2-10.6)    MYA from closest relative HPV129 
HPV219 13 1 5.4 (4.0-7.1)    MYA from its closest relative HPV219 
HPV220 17 1 19.9 (15.1-23.0)   MYA from all other Gamma-17 species HPV types 
HPV221 10 1 8.3 (5.8-11.5)   MYA from closest relative HPV142 
HPV222 19 1 19.2 (15.7-23.0)   MYA from all other Gamma-19 species HPV types 
 108 | P a g e  
 
50,000 years ago (Higham et al., 2014). Our MRCA prediction suggests that all the current HPV 
species diverged from what are currently their nearest relatives before the origin of modern 
humans. 
The MRCA of the Gamma-6 species was predicted to have existed 22 MYA (95% highest 
posterior density (HPD) 17.7-27.3), earlier than that of most other Gamma-PVs species. The 
MRCA of all other Gamma-species viruses and the Gamma-6 viruses was predicted to have 
occurred 46.8 MYA (95% HPD 42.9-51.3). The rest of the node divergence times are shown in 
Figure 3.4 with the 95% highest posterior densities and the posterior support values are shown 
in Supplementary Figure 3.5 in the appendix to chapter 3. 
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Figure 3. 4 Molecular divergence times of PVs.  
 Classification was based on (Bernard et al., 2010, de Villiers et al., 2004). Exact divergence 
estimates in million years (for the nodes corresponding to the 10 HPV types 95% highest 
posterior density are presented in Table 3.4). The novel types are indicated in red.  Posterior 
support values  are provided in the Supplementary Figure 3.5. 
3.3 DISCUSSION 
An analysis of phylogenetic trees generated from different genes of the ten novel South African 
Gamma-PVs and their closest known relatives indicated differences, ranging from slight to 
major, between the branch lengths and branching orders of phylogenetic trees constructed 
from different genes. The Ktreedist method was used as a preliminary test to quantify these 
differences. After confirming existence of incongruences a more rigorous test, the SH test using 
W-IQ-TREE was done. In W-IQ-TREE 80 known HPV sequences were used to construct gene 
phylogenetic trees that were then computed into the online tool to test for incongruence. 
Apart from SH test the W-IQ-TREE tool also tests for incongruence using other algorithms: the 
bp-RELL, p-KH, weighted KH and weighted SH, the c-ELW and the AU test (see legend to Table 
3.2 and also supplementary figures 3.6). The SH test consistent with the other tests shows p-
values of less than 0.05 indicative of differences among phylogenetic trees from different 
genes. To visualise the incongruence an example of 20 HPV types (the ten novel and their 
closest known HPV types) were used to construct an L1 and E7 trees as shown in Figure 3.2, and 
juxtaposed next to each other these trees show slightly different branching patterns.  
Differences between internal branches of phylogenetic trees constructed using different parts 
of the same HPV genomes have been described extensively elsewhere (Bravo and Felez-
Sanchez, 2015, Bravo and Alonso, 2004b, Schiffman et al., 2005a). These differences could 
imply the occurrence of recombination, as has been previously reported (Shah et al., 2010). 
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We did not, however find strong evidence of recombination among Gamma-HPV types. From 
the 80 full Gamma-PVs (70 known HPV types and the ten novel types) included in the analysis, 
only one strongly supporting a recombination event was detected. Recombination in Gamma-
PVs has been reported elsewhere (Bolatti et al., 2016). In that study, seven potential 
recombination events were reported using separate analyses of individual genes (rather than 
analysing full genomes). We detected few Gamma-PVs recombination events (Varsani et al., 
2006) reported 529 potential recombination events, yet only ten were true events. The 
phenomenon is not exclusive to Gamma-PVs, in Alpha-PVs recombination events have been 
well described (Angulo and Carvajal-Rodriguez, 2007, Narechania et al., 2005a). 
The difficulty in detecting recombination events in PVs relates to the technical difficulty of 
aligning highly divergent DNA sequences (Bravo and Felez-Sanchez, 2015, Varsani et al., 2006, 
Angulo and Carvajal-Rodriguez, 2007). Another factor is that most recombination detection 
methods are only designed to detect recombination events when one or both of the parental 
sequences have close relatives represented in the dataset being analysed (Van Doorslaer, 
2013).  Therefore, as more PVs are discovered, it becomes more likely that sequences closely 
related to the parents of recombinants will be included in recombination analyses. We also only 
included Gamma-PVs, in our recombination analysis dataset and our analysis was therefore 
only powered to detect for evidence of intra-genus recombination. However, this is probably 
not a major issue since the only convincing evidence of recombination in PVs that has so far 
been published has been between PVs in the same genus (Narechania et al., 2005a). In chapter 
2, it is reported that the ten novel Gamma-PVs are under no positive selection pressure but 
rather purifying selection (dn/ds <1).  
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It has been shown elsewhere that different PV genes are under different selection pressures 
(Rocha Rodríguez et al. (2012) and also that different genes have different evolutionary rates 
ranging between 2x10-8 and 5x10-9 substitutions per site per year (Shah et al., 2010, Rector et 
al., 2007). Thus, no single gene tree will accurately represent the evolutionary history of entire 
PV genomes (Van Doorslaer, 2013). 
Consequently, we report here phylogenetic tree incongruence with no evidence of 
recombination. It has been proposed that in such scenarios there is convergent as opposed to 
divergent evolution (Castoe et al., 2009). Convergent evolution can be defined as the 
independent evolution of similar features or characteristics in species of different lineages. 
We show here that the MRCA of HPV was predicted to have occurred about 50-60 MYA. This is 
comparable to work done by Chen et al. (Chen et al., 2007b), and that the MRCA of the 
Gamma-PVs existed about 45-67 (49.8) MYA. Further, we were able to show that within the 
Gamma-PV genus, the Gamma-6 species split from all the other Gamma species about 43-51 
(46.8) MYA, while Van Doorslaer and Mcbride (2016) and (Van Doorslaer and McBride, 2016) 
showed that Gamma-6 species last shared a common ancestor with other Gamma-PVs around 
60 MYA. Further, we showed that the MRCA of the Gamma-6 species occurred about 22 MYA, 
which concurs with Van Doorslaer and Mcbride (Van Doorslaer and McBride, 2016), who 
reported that the Gamma-6 species MRCA existed 23.4 MYA. We therefore hypothesise that 
the Gamma-6 species lost the E6 gene between 20 and 60 MYA. This suggests that E6 was lost 
before the evolution of hominoid primates between 10-20 MYA (Andrews, 1992). This implies 
two things: 1) that viruses lacking E6 may infect Old World and New World monkeys, suggesting 
that it could be productive to hunt for these viruses in primates, and 2) that the E6-minus 
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viruses co-evolved with their hosts over a long enough period of time for us to have been able 
to isolate them from current humans (assuming PV species specificity). Chen et al.  (Chen et al., 
2007b) had previously predicted the loss of the E6 gene to have occurred about 15-30 MYA, the 
estimate was based only on the L1 ORF of nine divergent papillomaviruses. Here, we have 
estimated this date using 214 papillomavirus L1 nucleotide sequences from all the genera 
containing HPV sequences.  
PVs lacking E6 have also been described in parrots (PePV1), donkeys (EaPV1) and bovines 
(Willemsen and Bravo, 2018). Presently, seven known human PVs of the Gamma-6 species lack 
the E6. The size of E6 (mean 253.5 nt) in the genomes of PVs infecting birds and turtles is about 
half the size of that in mammal-infecting PV genomes (mean 438 nt) (Willemsen and Bravo, 
2018). The larger size of the mammalian PV E6 accommodates a second E6 Zinc finger binding 
motif domain (Zanier et al., 2013): a domain that was possibly a duplication of an ancestral E6 
motif (Suarez and Trave, 2018). E6 mediated p53 degradation has been described as one of the 
hallmarks of HPV-mediated carcinogenesis, and the presence of this double motif may explain 
the increased likelihood of HPVs in causing cancer compared to PVs infecting birds and turtles.  
Gamma-PVs lack an E5 gene. The E5 gene is located between the early genes and the late genes 
and is thought to have evolved originally from a non-coding region that was integrated 
between the early and the late genes of an ancestral sequence belonging to the Alpha-PV 
lineage (Willemsen and Bravo, 2018). Willemsen and Bravo also suggest that integration of E5 
in this region promoted an adaptive radiation which yielded E6 and E7 proteins capable of 
degrading tumour suppressor proteins and facilitating carcinogenesis (Willemsen and Bravo, 
2018). This is supported by the fact that 1) E6 and E7 proteins in Alpha-PVs (together with E5) 
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have greater onocogenic potential as classified by IARC as compared to the E6 and E7 of 
Gamma-PVs (that lack E5) and 2) E5 has an evolutionary rate that is approximately twice that of 
the remainder of the PV genome. The integration of the E5 ORF was predicted to have occurred 
in an ancestral virus that existed 30-60 MYA (in the Cenozoic era) which eventually gave rise to 
the Alpha, Mu and Nu lineages; each of which has different cell tropisms and clinical 
manifestations (Bravo and Felez-Sanchez, 2015). Willemsen et al. (Willemsen and Bravo, 2018) 
inferred the appearance of the E5 oncogene occurred 53-58 MYA, well within the range of that 
predicted by Bravo et al (Bravo and Felez-Sanchez, 2015).  
We also reported the acquisition of E10 in HPV214, which we hypothesised coincided with E6 
loss as previously reported (Van Doorslaer et al., 2017a). We speculate that if the loss of E6 
occurred 20-60 MYA then E10 was acquired a few million years later or that the loss and gain 
might have occurred concurrently as a modification of E6 to E10. This is supported by the fact 
that the E10 ORF overlaps with the more conserved portion of the E6 scar (Van Doorslaer and 
McBride, 2016).  
We report divergence times from 7.6 to 20 MYA with most lying well within the origin times of 
many other known PVs. However, HPV211 of the Gamma-8 species branches earlier from the 
other five HPV types in this species, i.e. the MRCA of HPV211 and the other 5 Gamma-8 species 
types is predicted to have occurred 20 MYA. This implies that HPV211 is closer to the ancestral 
or parental sequence of Gamma-8 species compared to HPV112, HPV119, HPV168, HPV147, 
and HPV164, and hence, it is more likely to be major/minor parent than it can be a 
recombinant. The MRCA of HPV222 and the other 3 members of the Gamma-19 species is 19.2 
MYA. HPV222 branches from HPV161, HPV162 and HPV166 earlier than the others branch from 
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each other, also making it closer to the ancestral or parental sequence of the Gamma-19 
species. 
3.4 CONCLUSION 
In this work, we report on the evolutionary characterisation of Gamma-PVs including that of the 
novel HPV types. To get a deeper insight into the evolutionary processes that may influence the 
diversification of Gamma-PVs, we explored phylogenetic incongruences among different genes 
of the novel types, attempted to discover potential recombination events between all known 
Gamma-PVs, and also estimated the time scale for Gamma-PV evolution. Consequently, we 
report here phylogenetic tree incongruence without strong evidence of recombination. 
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Chapter 4: General Discussion and conclusions 
The aim of this thesis after the discovery of ten novel HPV viruses using NGS was to isolate the 
whole genomes of these ten viruses. This was achieved using back to back primers in a long-
range PCR using a touch down approach (in terms of annealing temperature) to increase primer 
binding specificity. Once the whole genomes were amplified, they were cloned and then deep 
sequenced using Illumina MiSeq to obtain full genome sequences. The characterisation of the 
full genomes of the novel viruses is described in the second chapter of this thesis. The genomic 
organisation, phylogenetic clustering, genomic variation, identification and description of the 
conserved functional domains in the novel HPV types is also discussed in chapter 2. The 
genomes of all the novel viruses belonged to the Gamma-PVs genera but from different species 
of the genus. A phylogenetic tree of all known HPVs is illustrated in Figure 2.4 and shows the 
distribution of these viruses among other Gamma-HPVs. Most showed classical genomic 
organisation of the Gamma-HPVs save for HP214, which lacked the E6 ORF and additionally had 
a putative ORF, the E10. HPV212, HPV220 and HPV222 also had a premature stop codon in the 
E4 ORF and hence their principal E4 protein was in the form of E1^E4 transcript. Several 
conserved domains were identified in the novel HPV types. Among these domains were: the 
Zinc finger binding domain, PBM, NLS and NES, ATP binding domain, transmembrane binding 
domain, furin cleavage sites, DNA recognition site, polyadenylation sites, TATA binding box and 
the E1 and E2 binding sites of the LCR. Functional experiments were not done and hence this 
thesis did not attempt to describe the functionality of these domains but rather was limited to 
identification of these domains.  
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Of the 10 novel viruses discovered, half showed no intra-sample variation (HPV211, HPV214, 
HPV216, HPV219, HPV221) while the other half (HPV212, HPV213, HPV215, HPV220 and 
HPV222) had several “variants” within individual samples.  
The intra-sample variation was however less than 0.5%. We ruled out PCR artefacts because 
two PCR runs were done for each potential novel HPV type, and Illumina sequencing has a very 
low error rate. The conclusion drawn from this is that HPVs evolve slowly and the low 
percentage variation is indicative of the robustness of host DNA polymerases. Also deduced 
from this chapter is the dn/ds ratios less than one, with a ratio of one indicating neutral 
selection, >1 diversifying positive selection and <1 negative or purifying selection (Chen et al., 
2009). These novel Gamma-HPVs are certainly under no positive selection pressure, immune or 
vaccine induced. Their negative selection maybe suggestive of the fact that they are commensal 
organisms. 
Chapter 3 focuses on the evolutionary dynamics of Gamma-HPVs with insights from 
phylogenetic incongruence, recombination and phylodynamic analysis (molecular divergence).  
For phylogenetic incongruence we focused only on the ten novel viruses and ten of their closest 
known HPV types in order to confirm what has been described for all known PVs: that different 
gene regions evolve differently (Harari et al., 2014, García-Vallvé et al., 2005). Once we 
confirmed phylogenetic incongruence of 20 Gamma-HPVs inclusive of the novel types, we then 
sought to establish these among all the 80 currently known and curated Gamma-HPV types. To 
this effect we did a SH test, which is more conclusive than the former. Having confirmed 
phylogenetic incongruences we then sought to investigate the existence of recombination 
events among the novel types and the known Gamma-HPVs. Information on HPV 
 118 | P a g e  
 
recombination is scarce and varied depending on the method used. Hence, in the 
recombination analysis all 80 Gamma-PVs (10 novel types included) were analysed. It is 
important to note that by so doing we only explored intra-genus recombination, it has been 
suggested that inter-genus recombination may occur (Shah et al., 2010). Our recombination 
results actually demonstrated one recombination result which is not highly supported and is a 
Gamma-HPV inter-species recombination between HPV4 (Gamma-1) and HPV130 (Gamma-10) 
and HPV162 (Gamma-19). Detecting recombination in HPV is hampered by technical difficulties 
in alignment and there is scarce information on this subject despite the fact that there are 
about 220 HPV types and that a lot of multiple infections have been reported in several studies, 
which theoretically is good grounds to suspect recombination (Bolatti et al., 2016). The fact that 
we do not know the whole list of HPVs, offers the potential of more recombination events 
being described once the discovery efforts are continued and more HPV sequences are made 
available in the repositories. The improvement of alignment algorithms is also essential in 
refining the search for recombination events among HPVs. In the phylodynamic analysis of HPV, 
we used a tree inferred from L1 nucleotide sequences of 214 PVs and included some animal PVs 
as an outgroup:  Two avian PVs; FcPV (Fringilla coelebs, the common chaffinch), PePV (Psittacus 
erithacus, the grey parrot) and one turtle PV: CcPV1 (Caretta caretta, the loggerhead turtle). 
The use of the L1 tree to infer phylogeny has been described elsewhere (Chen et al., 2007b). 
While it is generally known that different regions of the PV genome evolve differently, the L1 
gene is the most highly conserved and slight changes in this region are likely to reflect on the 
divergence times of the overall genome. The fact that they were discovered in Africa which is 
believed to be the cradle of mankind prompted further study into the timescale of these viruses 
compared to human evolution. The divergence times of the MRCA of HPV in this thesis was 
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predicted to have occurred 53.9 MYA. Several hominoid precursors lived in Africa, Europe and 
Asia between 10 and 20 MYA  (Andrews, 1992), the timing and spatiotemporal patterning of 
Neanderthal human precursors disappearance has only been radiocarbon dated to a limit of 
50,000 years ago (Higham et al., 2014). Our prediction suggests that all the current HPV species 
diverged from what are currently their nearest relatives before the origin of humans. 
In conclusion, ten novel Gamma-HPVs were discovered and characterised. Through various 
bioinformatics means we enriched our knowledge of this genus and other HPVs in general by 
including and comparing the novel types with already known HPV types.  
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Appendix 1: Appendix to Chapter 2 
 
 Supplementary Table 2.9 E1^E4 and E2^E8 spliced gene product prediction checklist. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 2.12 Alignment of the E7 proteins of the novel HPVs and closely related 
HPVs.  
The positions of the pRB binding domain and Zinc finger binding domains in E7 are indicated by 
the black boxes.  
 CHECK POINTS 
1 E1^E4 ATG is same as E1 ATG 
2 E8^E2 ATG is in +1 frame of E1 
3 E1 portion of E1^E4 ends with AG and spliced portion starts with GT within E2 
4 E8 portion of E8^E2 ends with AG and spliced portion starts with GT within E2 
5 Start of E2 in E8^E2 and E4 in E1^E4 is same 
6 There is an AG before start of E2 in E8^E2 and E4 in E1^E4 
7 E1^E4 stop codon = E4 stop codon 
8 E8^E2 stop codon = E2 stop codon 
9 E2 portion of E8^E2 is identical to C-terminus E2 
10 E4 portion of E1^E4 is identical to E4 
11  E4 portion of the E1∧E4  is in +1 frame of E2 
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Supplementary Figure 2.13 Alignment of the E1 proteins of the novel HPVs and closely related 
HPVs.  
The positions of the ATP binding sites are indicated by the black boxes 
 
 
Supplementary Figure 2.14 Alignment of the E1 proteins of the novel HPVs and closely related HPVs.  
The positions of the bipartite NLS and NES sites are indicated by the black boxes.  
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Supplementary Figure 2.15 Alignment of the L1 proteins of the novel HPVs and closely related 
HPVs.  
The positions of the NLS sites are indicated by the black boxes.  
 
 
 
Supplementary Figure 2.16 Alignment of the E2 proteins of the novel HPVs and closely related 
HPVs.  
The positions of the NLS sites and DNA recognition helix are indicated by the black boxes.  
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Supplementary Figure 2.17 Alignment of the L2 proteins of the novel HPVs and closely related 
HPVs.  
The positions of the NLS sites, transmembrane binding site and the Furin cleavage sites are 
indicated by the black boxes.  
 
 
 124 | P a g e  
 
Appendix 2: Appendix to Chapter 3 
 125 | P a g e  
 
 
               60            50             40              30             20             10              0 
In million years 
Supplementary Figure 3. 5 
Posterior support values of PV 
divergence estimates.  
Classification was based on 
(Bernard et al., 2010, de 
Villiers et al., 2004). Posterior 
support values are shown, the 
nodes corresponding to the 10 
HPV types are presented in 
Table 3.4, the novel types are 
indicated in red. 
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Supplementary Figure 3. 6A- F (below) Six Tables showing the Shimodaira-Hasegawa test 
results using W-IQ-Tree.    
 
 
 
Tree Key 
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